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Refractive errors, including myopia, are the most frequent eye disorders worldwide and an increasingly 
common cause of blindness. This genome-wide association meta-analysis in 160,420 participants and 
replication in 95,505 participants, increased the established independent signals from 37 to 161 and 
revealed high genetic correlation between Europeans and Asians (>0.78). Expression experiments and 
comprehensive in silico analyses identified retinal cell physiology and light processing as prominent 
mechanisms, and functional contributions to refractive error development in all cell types of the 
neurosensory retina, retinal pigment epithelium, vascular endothelium and extracellular matrix. Newly 
identified genes elicited novel mechanisms such as rod and cone bipolar synaptic neurotransmission, 
anterior segment morphology, and angiogenesis. Thirty-one loci resided in or near regions transcribing 
small RNAs, suggesting a role for post-transcriptional regulation. Our results support the notion that 
refractive errors are caused by a light-dependent retina-to-sclera signaling cascade, and delineate potential 




Refractive errors are common optical aberrations determined by mismatches in the focusing power of the 
cornea, lens and axial length of the eye. Their distribution is rapidly shifting towards myopia, or 
nearsightedness, all over the world. The myopia boom is particularly prominent in urban East Asia where 
up to 95% of twenty-year-olds in cities such as Seoul and Singapore have this refractive error1-4. Myopia 
prevalence is also rising throughout Western Europe and the USA, affecting ~50% of young adults in 
these regions5,6. While refractive errors can be optically corrected, even at moderate values they carry 
significant risk of ocular complications with high economic burden7-9. One in three individuals with high 
myopia (-6 diopters or worse) will develop irreversible visual impairment or blindness, mostly due to 
myopic macular degeneration, retinal detachment, or glaucoma10,11. At the other extreme, high hyperopia 
predisposes to strabismus, amblyopia and angle-closure glaucoma10,12.  
 Refractive errors result from a complex interplay of lifestyle and genetic factors. The most 
established lifestyle factors for myopia are high education, lack of outdoor exposure, and excessive near 
work3. Recent research has identified many genetic variants for refractive errors, myopia, and axial 
length13-25. Two large studies, the international Consortium for Refractive Error and Myopia (CREAM)26 
and the personal genomics company 23andMe, Inc.17,27 have provided the most comprehensive results. 28 
  Given that only 3.6% of the variance of the refractive error trait was explained by the identified 
genetic variants26, we presumed a high missing heritability. We therefore combined CREAM and 
23andMe, and expanded the study sample to 160,420 individuals from a mixed ancestry population with 
quantitative information on refraction for a genome-wide association (GWAS) meta-analysis. Index 
variants were tested for replication in an independent cohort consisting of 95,505 individuals from the UK 
Biobank. We conducted systematic comparisons to assess differences in genetic inheritance and 
distribution of risk variants between Europeans and Asians. Polygenic risk analyses were performed to 
evaluate the contribution of the identified variants to the risk of myopia and hyperopia. Finally, we 
integrated expression data and bioinformatics on the identified genes to gain insight into the possible 
mechanisms underlying the genetic associations.  
   
 RESULTS 
Susceptibility loci for refractive error  
We performed a GWAS meta-analysis on adult untransformed spherical equivalent (SphE) using 
summary statistics from 37 studies from CREAM and on age of diagnosis of myopia (AODM) from two 
cohorts from 23andMe (Supplementary Figure 1, Supplementary Table 1a)26,27. Analyses were based on 
~11 million genetic variants (SNPs, insertions and deletions) genotyped or imputed to 1000 Genomes 
Project Phase I reference panel (version 3, March 2012 release29) that passed extensive quality control 
(Supplementary Figures 2-4, Supplementary Table 1b).  
 Meta-analyses were conducted in three stages: Stage 1 CREAM (CREAM-EUR, N=44,192; 
CREAM-ASN, N=11,935); Stage 2 23andMe (N=104,293; Online Methods); Stage 3 joint meta-analysis 
of Stage 1 and 2. As CREAM and 23andMe applied different phenotype measures, we used signed Z-
scores as the mean per-allele effect size and assigned equal weights to CREAM and 23andMe. We 
identified 7,967 genome-wide significant genetic variants clustering in 140 loci (Figure 1a,b; 
Supplementary Figure 5-6, Supplementary Table 2-5, Supplementary Data 1-2), replicating all 37 
previously discovered loci and finding 104 novel loci. We applied genomic control at each stage and 
checked for population stratification using LD score regression30 (Stage 1-2  inflation factors (λGC) <1.1 
and  LD score regression intercepts (LDSCintercept) 0.892-1.023; Supplementary Table 6; Supplementary 
Figure 6- 7). At Stage 3, we observed a genomic inflation (λGC=1.129; Supplementary Figure 6), 
probably due to true polygenicity rather than population stratification or cryptic relatedness31. LDSCintercept 
remained undetermined due to mixed ancestry. 
To detect the presence of multiple independent signals at the discovered loci, a stepwise 
conditional analysis was performed with GCTA-COJO32 on summary statistics from all European cohorts 
(N=148,485) using the Rotterdam Study I-III (RS I-III) as a reference panel for LD structure (NRSI-
III=10,775). This analysis yielded 27 additional independent variants, resulting in a total of 167 loci 
(Supplementary Table 2).  
We advanced these loci for replication in a GWAS of refractive error carried out by the UK 
Biobank Eye & Vision (UKEV) Consortium (N=95,505) 33 (Online Methods). Six out of the 167 variants 
were not considered for replication analysis. One of these five variants (rs3138141, RDH5) was identified 
previously and therefore still considered as a refractive error risk variant26,27. The remaining 161 genetic 
variants were tested for replication. 86% (138/161) of the candidate variants replicated significantly: 104 
(65%) replicated surpassing genome-wide significance and 34 replicated surpassing Bonferroni 
correction (P<3.0x10-4; 21.1%); another 12 showed nominal evidence for replication (0.05<P<3.0x10-4; 
7.5%) and only 11 (7%) did not replicate at all (Table 1, Supplementary Table 2). 
 As CREAM and 23andMe employed different phenotypic outcomes, we evaluated consistency of 
genotypic effects by comparing marker-wise additive genetic effect sizes (in units diopters per risk allele 
variant) for SphE from CREAM-EUR against those (in units log(HR) per risk allele variant) for AODM 
from 23andMe. All variants strongly associated with either outcome (P<0.001) were concordant in 
direction-of-effect, and had highly correlated effect sizes (Figure 2a,b; Supplementary Figure 8). For 
these variants a 10% decrease in log(HR) for AODM, indicating an earlier age-at-myopia onset, was 
associated with a decrease of 0.15 diopters in SphE. A quantitative analysis for all common SNPs 
(MAF>0.01; HapMap3) using LD score regression yielded a genetic correlation of 0.93 (95% CI 0.86-
0.99; P=2.1x10-159), confirming that effect sizes for both phenotypic outcomes were closely related.  
 
Gene annotation of susceptibility loci 
We annotated all genetic variants with wANNOVAR using the University of California Santa Cruz 
(UCSC) Known Gene database34,35. The identified 139 genetic loci were annotated to 208 genes and 
known transcribed RNA genes (Table 1, Supplementary Table 2, Online Methods). The physical 
positions of the lead genetic variants relative to protein-coding genes are shown in Figure 1c. 86% of the 
identified variants were either intragenic or less than 50 kb from the 5’or 3’ end of the transcription start 
site. We found seven exonic variants (Supplementary Table 7) of which two had MAF≤0.05: rs5442 
(GNB3) and rs17400325 (PDE11A). The index SNP in the GNB3 locus with MAF 0.05 in Europeans is a 
highly conserved missense variant (G272S) predicted to be damaging by PolyPhen-236 and SIFT37. 
PDE11A is presumed to play a role in tumorigenesis, brain function, and inflammation38. The index SNP 
in the PDE11A locus with MAF 0.03 in Europeans is also a highly conserved missense variant (Y727C); 
this variant was predicted to be damaging by PolyPhen36, SIFT39 and align GVGD40,41.The other exonic 
variants, rs1064583 (COL10A1), rs807037 (KAZALD1), rs1550094 (PRSS56), rs35337422 (RD3L), and 
rs6420484 (TSPAN10) were not predicted to be damaging. 
 The most significant variant (Stage 3; rs12193446, P=4.21x10-84) resides on chromosome 6 
within a non-coding RNA, BC035400, in an intron of the LAMA2 gene. This locus had been identified 
previously, but our current fine mapping redefined the most associated variant. The function and potential 
downstream target sites for BC035400 are currently unknown. The previously most strongly associated 
variant, rs524952 on chromosome 15 near GJD2, was the second most significant variant (P=2.28x10-65).  
Post-GWAS analyses 
We performed two gene-based tests, fastBAT42 and EUGENE43, and applied a functional enrichment 
approach using fgwas44 (Online Methods). With fastBAT, we identified 13 genes at P <2.0x10-6, one of 
which (CHD7) had been identified previously26,27. Using EUGENE, we found 7 genes at P <2.0x10-6 after 
incorporation of blood eQTLs. With fgwas, we identified 6 loci, which could be annotated to 9 genes, at 
posterior probability >0.9. Two genes (HMGN4 and TLX1) showed significant associations in two or 
more approaches. Taken together, these post-GWAS approaches resulted in a total of 22 additional 
candidate loci for refractive error, annotated to 25 genes (Supplementary Table 8). This increases the 
overall number of significant genetic associations to 161 candidate loci. 
Polygenic risk scores 
We calculated polygenic risk scores (PGRS)45 per individual at various P thresholds (Online Methods) for 
Rotterdam Study I-III (RS I-III; N=10,792) after recalculating P and Z-scores of variants from Stage 3 
excluding RS I-III. We found the highest fraction of phenotypic variance (7.8%) explained with 7,307 
variants at P value threshold 0.005 (Supplementary Table 9). A PGRS based on these variants 
distinguished well between individuals with hyperopia and myopia at the lower and higher deciles (Figure 
3); those in the highest decile had a 40-fold increased risk of myopia. When the PGRS was stratified for 
the median age (<63 or >63+ yrs), we found a significant difference in the variance explained (<63 yrs 
8.9%; 63+ yrs 7.4%; P 0.0038). The variance explained by PGRS was not significantly different between 
males and females (8.3% vs 7.5%; P 0.13). The predictive value (area under the receiver operating 
characteristic curve, AUC) of the PGRS for myopia versus hyperopia adjusted for age and gender was 
0.77 (95% CI=0.75–0.79), a 10% increase compared to previous estimations46.  
Trans-ethnic comparison of genotypic effects 
To explore potential ancestry differences in the identified refractive error loci, we calculated the 
heritability explained by common genetic variants (SNP-h2) for Europeans and Asians using LD score 
regression47. SNP-h2 was 0.214 (95% CI 0.185- 0.243) and 0.172 (95% CI 0.154- 0.190) in the European 
samples (CREAM-EUR and 23andMe), while it was only 0.053 (95% CI -0.025- 0.131) in the Asian 
sample (CREAM-EAS). Next, we estimated the genetic correlation between Europeans and Asians by 
comparing variant effect size for common variants using Popcorn48 (Online Methods). Two genetic 
correlation metrics were calculated T; First, a genetic effect correlation (ρge) that quantifies the 
correlation in SNP effect sizes between Europeans and Asians without taking into account ancestry-
related differences in allele frequency; and second, a genetic impact correlation (ρgi) that estimates the 
correlation in variance-normalized SNP effect sizes between the two ancestry groups (Table 2). Estimates 
of ρge were high between Europeans and Asians, but significantly different from 1 (0.79 and 0.80, 
respectively at P <1.9x10-6; Table 2), indicating a clear genetic overlap but a difference in per allele effect 
size. Estimates of ρgi were similarly high (>0.8), but not significantly different from 1 for the correlation 
between CREAM-EUR and CREAM-ASN (P=0.065), indicating that the genetic impact of these alleles 
may still be similar.  
 
In silico pathway analysis 
We used an array of bioinformatics tools to investigate potential functions and pathways of the associated 
genes. We first employed DEPICT49 to perform a gene set enrichment analysis, a tissue type enrichment, 
and a gene prioritization analysis, on all variants with P <1.00x10-5 from Stage 3. The gene set 
enrichment analysis resulted in 66 reconstituted gene sets, of which 55 (83%) were eye-related. To reduce 
redundancies between pathways, we clustered the significant pathways into 13 meta gene sets (false 
discovery rate (FDR) <5% and a P <0.05) (Supplementary Note, Figure 4, Supplementary Table 10). The 
most significant gene set was the ‘abnormal photoreceptor inner segment morphology’ (MP:0003730; 
P=1.79x10-7). The eye-related meta gene sets consisted of the ‘thin retinal outer nuclear layer’ 
(MP:0008515; 27 (55%) gene sets), ‘detection of light stimulus’ (GO:0009583; 13 (24%) gene sets), 
‘nonmotile primary cilium’ (GO:0031513; 4 (6%) gene sets), and ‘abnormal anterior eye segment 
morphology’ (MP:0005193; 4 (6%) gene sets). The first three meta gene sets had a Pearson’s correlation 
> 0.6. Interestingly, RGR, RP1L1, RORB and GNB3 were present in all of these meta gene sets. Retina 
was the most significant tissue of expression according to the tissue enrichment analysis (P=1.11 x 10-4, 
FDR <0.01). From the gene prioritization according to DEPICT, 7 genes were highlighted as the most 
likely causal genes at P<7.62x10-6 and FDR<0.05: ANO2, RP1L1, GNB3, EDN2, RORB and CABP4.  
 Next, we performed a canonical pathway analysis on all genes annotated to the variants of Stage 
3 using Ingenuity Pathway Analysis (See URLs). All genes were run against the IPA database 
incorporating functional biological evidence on genomic and proteomic expression based on regulation or 
binding studies. IPA identified “Glutamate Receptor Signaling” with central player Nf-kB gene as the 
most significant pathway after correction for multiple testing (ratio of the number of molecules 8.8% and 
Fisher's Exact test P=1.56x10-4; Supplementary Figure 9).  
 
From disease-associated loci to biological mechanisms 
We adapted the scoring scheme designed by Fritsche et al.50 to highlight genes for which there is 
biological plausibility for a role in eye growth50. We used 10 equally rated categories (Online Methods; 
Figure 5; Supplementary Table 11; Supplementary Note). One-hundred-and-nine index variants replicated 
in two or more individual cohorts; we found evidence for seven genetic variants with eQTL effects in 
multiple tissue types; nine exonic variants, of which seven predicted protein-alterations (Supplementary 
Table 7); 31 RNA genes, five located in the 3’ or 5’UTR (Supplementary Table 12, Supplementary Figure 
10), 84 genes resulting in an ocular phenotype in humans (Supplementary Table 13) and 36 in mice 
(Supplementary Table 14); 172/212 (81%) genes expressed in human ocular tissue (Supplementary Note, 
Supplementary Table 15); 41 genes identified by DEPICT at P <5.4x10-4 and FDR<0.05 and 45 genes 
contributed to the most significant canonical pathways of IPA. Notably, 48 of the associated genes encode 
known drug targets (Supplementary Table 16). 
  The gene with the highest biological plausibility score (score=8) was GNB3, a highly conserved 
gene encoding a guanine nucleotide-binding protein expressed in rod and cone photoreceptors and ON-
bipolar cells51. GNB3 participates in signal transduction through G-protein-coupled receptors and 
enhances the temporal accuracy of phototransduction and ON-center signaling in the retina51. As 
described above, the index SNP harbors a missense variant associated with refractive errors. Non-
synonymous mutations within GNB3 are known to cause syndromic congenital stationary night 
blindness52 in humans, progressive retinopathy and globe enlargement in chickens51, and abnormal 
development of the photoreceptor-bipolar synapse in knock-out mice53,54.  
Other genes highly ranked (score=7) include CYP26A1, GRIA4, RDH5, RORB, and RGR, all 
previously associated with refractive error, and one newly identified gene: EFEMP1. EFEMP1 encodes a 
member of the fibulin family of extracellular matrix glycoproteins, and is found pan-ocularly including in 
the inner nuclear layer and Bruch’s membrane. Mutations in this gene lead to specific macular 
dystrophies55, while variants have also been shown to co-segregate with primary open-angle glaucoma56 
and associate with optic disc cup area57.  
 Several other genes are noteworthy for their function. CABP4, a calcium-binding protein 
expressed in cone and rod photoreceptor cells, mediates Ca2+-influx and glutamate release in the 
photoreceptor-bipolar synapse58. Mutations in this gene have been described in congenital cone-rod 
synaptic disorder59, a retinal dystrophy associated with nystagmus, photophobia, and, remarkably, high 
hyperopia. KCNMA1 encodes pore-forming alpha subunits of Ca2+-activated K+ (BK) channels. These 
channels regulate synaptic transmission exclusively in the rod pathway60. ANO2 is a Ca2+-activated Cl- 
channel recently reported to regulate retinal pigment epithelial (RPE) cell volume in a light-dependent 
manner64. EDN2 is a potent vasoconstrictor that binds to two G-protein-coupled receptors, EDNRA, which 
resides on bipolar dendrites, and EDNRB, which is present on Mueller and horizontal cells. Both receptors 
are also present on choroidal vessels65, implying that the choroid as well as retinal cells are target sites for 
this gene. RP1L1 is expressed in cone and rod photoreceptors where it is involved in the maintenance of 
microtubules in the connecting cilium66. Mutations in this gene cause dominant macular dystrophy and 
retinitis pigmentosa67. We replicated two genes known to cause myopia in family studies. FBN1 harbors 
mutations causing with Marfan (OMIM #154700) and Weil Marchesani (OMIM #608328) syndrome; 
PTPRR was one of the candidates in the MYP3 locus, which was found by linkage in families with high 
myopia68.  
 The location of rs7449443 (P=3.58x10-8) is notable as it resides in between DRD1 and FLJ16171. 
DRD1 encodes dopamine receptor 1 and is known to modulate dopamine receptor 2-mediated events69,70. 
The dopamine pathway has been implicated in myopia pathogenesis in many studies69,71. SNPs in and 
near other genes involved in the dopamine pathway (dopamine receptors, synthesis, degradation, and 
transporters)72-74 did not reveal genome-wide significant associations (Supplementary Note, 
Supplementary Table 17; Supplementary Figure 11). 
There were 31 genetic variants in or near DNA structures transcribing RNA genes (non coding 
RNA, linc RNAs, tRNAs, snoRNas, rRNAs). Notably, five were in the transcription region and thirteen 
were in the vicinity (>0 kb and ≤50 kb) of start or end of the RNA gene transcription region. They 
received low scores, since many have no reported function or disease association to date (Figure 5, 
Supplementary Figure 10, Supplementary Table 12). Our ranking of genes based on functional 
information existing in the public domain does not necessarily represent the true order of importance for 
refractive error pathogenesis. The observation that genes with strong statistical association were 
distributed over all scores supports this concept. Nevertheless, this list may help to select genes for 
subsequent functional studies. 
Finally, integration of all our findings, supported by literature, allowed us to annotate a large 
number of genes to ocular cell types (Figure 6). Remarkably, all cell types of the retina harbored 
refractive error genes, as well as the RPE, vascular endothelium, and extracellular matrix.  
  
Genetic pleiotropy  
We performed a GWAS catalogue look up using FUMA to investigate overlap of genes with other 
common traits (Supplementary Figure 12)75. Refractive error and hyperopia were replicated significantly 
after correcting for multiple testing (adjusted P value=1.44x10-52 and 9.34x10-9, respectively). We found 
significant overlap with 74 other traits, of which height (adjusted P value=1.11x10-10), obesity (adjusted 
P=1.38x10-10), and BMI (adjusted P=4.05x10-7) were most important. Ocular diseases significantly 
associated were glaucoma (optic cup area, intraocular pressure; adjusted P=2.69x10-5 and 3.01x10-5, 
respectively) and age-related macular degeneration (adjusted P value=1.27x10-3). 
 
DISCUSSION 
Myopia may become the leading cause of world blindness in the near future, a grim outlook for which 
current counteractions are still insufficient11,76. To improve understanding of the genetic landscape and 
biology of refractive error, we conducted a large GWAS meta-analysis in 160,420 participants of mixed 
ancestry and replicated in 95,505 participants. This led to the identification of 139 independent 
susceptibility loci by single variant analysis and 22 additional loci through post-GWAS methods, a four-
fold increase in refractive error genes. The majority of annotated genes were found to be expressed in the 
human posterior segment of the eye. Using in silico analysis, we identified significant biological 
pathways, of which retinal cell physiology, light processing, and, specifically, glutamate receptor 
signaling were the most prominent mechanisms. Our integrated bio-informatic approach highlighted 
known ocular functionality for many genes.  
  To ensure robustness of our genetic associations, we included studies of various designs and 
populations, sought replication in an independent cohort of significant sample size, and stringently 
accounted for population stratification by performing genomic control at all stages of the meta-analysis77. 
We combined studies with outcomes based on actual refractive error measurements as well as on self-
reported age-of-myopia-onset, and found the direction-of-effect of the associated variants, as well as their 
effect size, to be remarkably consistent. Combining two different outcome measures may appear 
unconventional, but age of onset and refractive error have been shown to be very tightly 
correlated11,28,78,79. 78,79Moreover, the high genetic correlation (93%) of common SNPs between the two 
phenotypes underscores their similarity. Most compelling evidence was provided by replication of 86% of 
the discovered variants in the independent UKEV which also used conventional refractive error 
measurements. This robustness indicates that both phenotypic outcomes can be used to capture a shared 
source of genetic variation. In addition, we found trans-ethnic replication of significant loci, and a high 
correlation of genetic effects of common variants in the Europeans and Asians. Our findings support a 
largely shared genetic predisposition to refractive error and myopia in the two ethnicities, although 
ancestry-specific allelic effects may exist. The low heritability estimate in Asians may, in part, be 
explained by the low representation of this ethnicity in our study sample. Alternatively, it may imply that 
environmental factors explain a greater proportion of the phenotypic risk and recent rise in myopia 
prevalence in this ancestry group80.  
 Limitations of our study were the possibility of false negative findings due to genomic control, 
and underrepresentation of studies with Asian ancestry. Heterogeneity of observed effect estimates was 
large for several associated variants, but not unexpected, given the large number of collaborating studies 
with varying methodology.  
 Although neurotransmission was previously suggested pathway26,27, our current pathway analyses 
provide more in-depth insights into the retinal circuitry driving refractive error. DEPICT identified ‘thin 
retinal outer nuclear layer’, ‘detection of light stimulus’, and ‘nonmotile primary cilium’ as the most 
important meta-gene sets. These are the main characteristics of photoreceptors, which are located in the 
outer retina and contain cilia. These photosensitive cells drive the phototransduction cascade in response 
to light, which in turn induces visual information processing. IPA pointed towards glutamate receptor 
signaling as the most significant pathway. Glutamate is released by photoreceptors and determines 
conductance of retinal signaling to the ON and OFF bipolar cells81. Our functional gene look ups provide 
evidence that rod (CLU) as well as cone (GNB3) bipolar cells play a role. Taken together, these findings 
strongly suggest that light response and light processing in the retina are initiating factors leading to 
refractive error. 
The genetic association with light-dependent pathways may also link to the well-established 
protective effect of outdoor exposure on myopia. We found suggestive evidence for a genetic association 
with DRD1. The dopaminergic pathway has been studied extensively in animal models for its role in 
controlling eye growth in response to light69,71,82-91. DRD1 was found to be a mediator in this process, as 
bright light increased DRD1 activity in the bipolar ON-pathway, and diminished form-deprivation 
myopia in mice. Blockage of DRD1 reversed this inhibitory effect92. We did not find evidence for direct 
involvement of other genes in the dopamine pathway, but GNB3 may be an indirect modifier as it is a 
downstream signaling molecule of dopamine and has been shown to influence availability of the 
dopamine transporter DAT93. Although a promising target for therapy, further evidence of DRD1 in 
human myopiagenesis is warranted.  
Novel pathways elicited by the newly identified genes are anterior segment morphology 
(TCF7L2, VIPR2, MAF) and angiogenesis (FLT1). In addition, the high number of variants residing near 
small RNA genes suggests that post-transcriptional regulation is an important mechanism, as these RNAs 
are known to play a distinct and central regulatory role in cells94. These findings will serve as leads for 
future studies performing detailed mapping of cellular networks, and functional studies on genes 
implicated in ocular phenotypes, harboring protein-altering variants, and proven drug targets.  
 Our evaluation of shared genetics between refractive error and other disease-relevant phenotypes 
highlighted overlap with anthropometric traits such as height, obesity, and body mass index. This could 
give valuable additional clues as to the phenotypic outcomes of perturbations of some of the networks 
identified. 
  Our genetic observations add credence to the current notion that refractive errors are caused by a 
retina-to-sclera signaling cascade that induces scleral remodeling in response to light stimuli. The concept 
of this cascade originates from various animal models showing that form deprivation, retinal defocus and 
contrast, ambient light, and wavelength can influence eye growth in young animals95-97. Cell-specific 
moieties in this putative signaling cascade in humans were largely unknown, although animal models 
implicated GABA, dopamine, all-trans-retinoic acid and TGF-β69,91,98,99. Our study provides a large 
number of new molecular candidates for this cascade, and clearly shows that a wide range of neuronal cell 
types in the retina, the RPE, the vascular endothelium, as well as components of the extracellular matrix 
are implicated. The many interprotein relationships exemplify the complexity of eye growth, and provide 
a challenge to develop strategies to prevent pathological eye elongation.  
 In conclusion, by using a cross-ancestry design in the largest study population on common 
refractive errors to date, we uncovered numerous novel loci and pathways involved in eye growth. Our 
multi-disciplinary approach incorporating GWAS data with in silico analyses and expression experiments 
provides an example for the design of future genetic studies for complex traits. Additional genetic insights 
into refractive errors will be gained by increasing sample size and genotyping depth, by performing 
family studies to identify rare alleles of large effects, and by evaluating population extremes. Our list of 
plausible genes and pathways provide a plethora of data for future studies focusing on gene-environment 
interaction, and on translation of GWAS findings into starting points for therapy.  
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Figure 1. GWAS meta-analysis identifies 140 loci for refractive error (Stage 3) 
 
(a) We conducted a meta-analysis of genome-wide single-variant analyses for >10 million variants in 
160,420 participants of CREAM and 23andMe (Stage 3). Shown is the Manhattan plot depicting P for 
association, highlighting new (P < 5 × 10−8 for the first time; green) and known (dark grey) refractive error 
loci previously found using HapMap II imputations from Kiefer et al.27 and Verhoeven et al.26 (Table 1). 
The horizontal lines indicate suggestive significance (P=1×10−5) or genome-wide significance 
(P=5×10−8). (b) We compared the minor allele frequencies of the 140 discovered index variants based on 
1000G (blue: Europeans; red: Asians) to the minor allele frequencies of the previously found genetic 
variants based on HapMap II (green: Europeans; purple: Asians). Observed are an increase in genetic 
variants found across all minor allele frequency bins increase, including the lower minor allele frequency 
bins. (c) We annotated the 167 loci to genes using wANNOVAR. Shown are the distances between index 
variants from the nearest gene and its gene on the 5’ and/or 3’ site. The majority of index variants (84%) 
were at a distance of less than 50 kb up- or downstream from the annotated gene.  
 
 
Figure 2. Correlation of statistical significance and effect size of SNPs based on spherical equivalent 
(SphE) in diopters and age of diagnosis of myopia (AODM) in years. 
 
 (a) P comparison of all genetic variants with P < 1.0 x 10-3 (n=7249) between CREAM meta-analysis 
(Stage 1) and 23andMe (Stage 2) meta-analysis. Shown is the overlap (red) and the difference (green) in 
P signals per cohort for genetic variants. Green genetic variants are only genome wide significant in 
either CREAM or 23andMe. Blue: genetic variants with P between 5.0 x 10-8 and 1.0 x 10-3 in both 
CREAM and 23andMe. (b) Comparison of effects (SphE and logHR of AODM in years; P < 1.0 x 10-3; 
n=7249) between CREAM and 23andMe. Same color code was applied as in (a). The effects were 
concordant in their direction of effect on refractive error. We performed a simple linear regression 
between the effects of CREAM and 23andMe; the regression slope is -0.15 diopters per logHR of AODM 
in years.  
 
Figure 3. Risk of refractive error per decile of polygenic risk score (Rotterdam Study I-III, 
N=10,792) 
Distribution of refractive error in subjects from Rotterdam Study I–III (N=10,792) as a function 
of the optimal polygenic risk score (including 7,303 variants at P ≤ 0.005 explaining 7.8% of the variance 
of SphE; Supplementary Table 9). Mean OR of myopia (black line) was calculated per polygenic risk 
score category using the lowest category as a reference. High myopia (SphE ≤-6 D), moderate myopia 
(SphE >-6 D & ≤ −3 D), low myopia (SphE > −3 D & <-1.5 D), emmetropia (SphE ≥ −1.5 D and ≤ 1.5 
D), low hyperopia (SphE > 1.5 D & < 3 D), moderate hyperopia (SphE ≥ 3 D & 6 D), high hyperopia 
(SphE ≥ 6 D).  
 
Figure 4. Visualization of the DEPICT gene-set enrichment analysis based on loci associated with 
refractive error and the correlation between the (meta)gene sets 
(a) Shown are the 66 significantly enriched reconstituted gene sets clustered into thirteen meta gene sets 
based on the gene set enrichment analysis of DEPICT (pairwise Pearson correlations; P < 0.05). All 
genetic variants with a P < 1 × 10−5 in the GWAS meta-analysis of stage 3 (n=21,073) and an FDR < 
0.05 were considered. (b) Visualization of the interconnectivity between gene sets (n=13; pairwise 
Pearson correlations; P < 0.05) of the meta gene set ‘Detection of Light Stimulus’ (GO:0009583). (c) 
Visualization of the interconnectivity between gene sets (n=27; pairwise Pearson correlations; P < 0.05) 
of the largest meta gene set ‘Thin Retinal Outer Nuclear Layer’ (MP:0008515). In all panels, (meta)gene 
sets are represented by nodes colored according to statistical significance, and similarities between them 
are indicated by edges scaled according to their correlation; Pearson’s r ≥ 0.2 are shown in panel (a) and 
Pearson’s r ≥ 0.4 are shown in panel (b,c). 
 
Figure 5. Genes ranked according to biological and statistical evidence 
Genes were ranked (orange) based on 10 equal categories which can be divided in four categories: 
internal replication of genetic variant in more than two cohorts (purple; CREAM-EUR, CREAM-ASN 
and/or 23andMe), annotation (light blue; genetic variant harboring an exonic protein altering variant or 
non-protein altering variant, genetic variant residing in a 5’ or 3’ UTR region of a gene or transcribing an 
RNA structure), expression (yellow; eQTL, expression in adult human ocular tissue, expression in 
developing ocular tissue), biology (dark yellow; ocular phenotype in mice, ocular phenotype in humans), 
pathways (green; DEPICT gene-set enrichtment, DEPICT gene prioritization analysis and canonical 
pathway analysis of IPA). We assessed genes harboring drug targets (salmon red), but did not assign a 
scoring point to this category. 
 
*Only one point can be assigned in the category ‘ANNOTATION’, even though it has four columns (i.e. 
a genetic variant is located in only 1 of these four categories). 
 
Figure 6. Schematic representation of the human eye, retinal cell types, and functional sites of 
associated genes  
We assessed gene expression sites and/or functional target cells in the eye for all genes using our 
expression data and literature and data present in the public domain. The genes appear to be distributed 
across virtually all cell types in the neurosensory retina, in the RPE, vascular endothelium and 
extracellular matrix; i.e., the route of the myopic retina-to-sclera signalling cascade. 
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Table 1. Results of the meta-analysis of CREAM and 23andMe for the previously-identified loci and a subset of the newly-identified loci, 1 
and replication in UK Biobank 2 
 3 
Table 1a Replication of the HapMap II index variants for refractive error per locus in the Stage 3 meta-analysis 4 














rs12193446 6 129820038 BC035400,  LAMA2 A G 0.906 NA -19.43 -- 4.21E-84 16.8 5.72E-15 150,26
9 
4.60E-106 
rs524952 15 35005886 GOLGA8B, GJD2 A T 0.475 0.507 -17.08 -- 2.28E-65 67.2 0.015 160,15
0 
1.60E-103 
rs7744813 6 73643289 KCNQ5 A C 0.591 0.602 -14.56 -- 5.43E-48 35 0.001 160,09
1 
1.00E-75 
rs11602008 11 40149305 LRRC4C A T 0.822 0.749 13.98 ++ 2.12E-44 22.5 1.56E-10 157,50
5 
2.90E-47 
rs3138141 12 56115778 BLOC1S1-
RDH5,RDH5 
A C 0.214 0.147 13.8 ++ 2.46E-43 3.2 5.05E-07 157,53
1 
2.30E-56 
rs10500355 16 7459347 RBFOX1 A T 0.354 0.133 -13.73 -- 6.49E-43 9.1 2.93E-07 160,13
9 
2.50E-48 
rs72621438 8 60178580 SNORA51, CA8 C G 0.642 0.609 -13.14 -- 2.03E-39 38.4 0.006 160,12
8 
1.80E-49 
rs1550094 2 233385396 CHRNG, PRSS56 A G 0.701 0.705 12.74 ++ 3.64E-37 26.3 0.003 159,42
2 
4.10E-59 
rs2908972 17 11407259 SHISA6 A T 0.415 0.484 -11.13 -- 9.46E-29 23 0.254 160,12
3 
6.10E-29 
rs7829127 8 40726394 ZMAT4 A G 0.792 0.897 -10.91 -- 1.02E-27 15.9 2.77E-04 160,13
2 
3.10E-22 
rs6495367 15 79375347 RASGRF1 A G 0.408 0.399 -10.2 -- 1.95E-24 0 0.667 160,14
4 
7.20E-37 
rs11145465 9 71766593 TJP2 A C 0.212 NA -9.55 -- 1.35E-21 46.3 0.1722 153,17
4 
1.00E-10 
rs1649068 10 60304864 BICC1 A C 0.475 0.504 -9.44 -- 3.77E-21 0 0.712 160,14
4 
7.50E-11 
rs7692381 4 81903049 C4orf22, BMP3 A G 0.763 0.63 9.4 ++ 5.55E-21 0 0.013 160,13
4 
7.50E-13 
rs56075542 2 146882415 BC040861, 
PABPC1P2 
T G 0.552 0.472 -8.99 -- 2.39E-19 13.9 0.001 159,47
8 
1.30E-18 
rs7895108 10 79061458 KCNMA1 T G 0.351 0.118 -8.87 -- 7.56E-19 32.8 0.021 160,14
0 
1.10E-27 
rs7624084 3 141093285 ZBTB38 T C 0.568 0.633 -8.81 -- 1.24E-18 18.5 0.018 160,15
1 
6.50E-17 
rs62070229 17 31227593 MYO1D, TMEM98 A G 0.807 0.874 8.58 ++ 9.64E-18 0 0.416 156,57
0 
1.30E-18 
rs2855530 14 54421917 BMP4 C G 0.507 0.474 -8.58 -- 9.87E-18 41.7 0.19 160,09
2 
4.80E-22 
rs7662551 4 80537638 LOC100506035, 
PCAT4 
A G 0.723 0.558 8.53 ++ 1.47E-17 19.4 0.265 160,14
7 
6.00E-12 
rs9517964 13 100717833 ZIC2,PCCA T C 0.589 0.786 8.42 ++ 3.68E-17 0 0.02 160,12
1 
3.40E-20 
rs1954761 11 105596885 GRIA4 T C 0.371 0.377 -8.4 -- 4.57E-17 0 0.911 160,12
2 
1.20E-16 
rs745480 10 85986554 LRIT2,LRIT1 C G 0.511 0.418 8.31 ++ 9.26E-17 67.3 0.081 159,50
4 
8.20E-18 
rs2573081 2 178828507 PDE11A C G 0.524 0.538 8.21 ++ 2.18E-16 47.6 0.167 160,12
6 
1.60E-29 
rs17428076 2 172851936 HAT1, METAP1D C G 0.768 0.854 -8.18 -- 2.77E-16 0 0.003 160,15
1 
7.50E-08 
rs2155413 11 84634790 DLG2 A C 0.482 0.655 -7.76 -- 8.85E-15 0 2.99E-04 159,50
4 
1.10E-17 
rs11178469 12 71275137 PTPRR T C 0.752 0.638 -7.4 -- 1.33E-13 0 0.6989 160,13
9 
2.60E-04 
rs1858001 1 207488004 C4BPA,CD55 C G 0.676 0.415 7.28 ++ 3.45E-13 59.6 0.02 160,14
9 
6.70E-20 
rs4793501 17 68718734 KCNJ2, BC039327 T C 0.575 0.444 -7.21 -- 5.53E-13 0 0.592 160,15
0 
3.70E-12 
rs7042950 9 77149837 RORB A G 0.732 0.392 6.8 ++ 1.07E-11 0 0.912 16 ,15
3 
2.90E-18 
rs4687586 3 53837971 CACNA1D C G 0.691 NA -6.55 -- 5.86E-11 0 0.605 150,21
7 
1.60E-08 
rs2753462 14 60850703 JB175233, C14orf39 C G 0.296 0.568 -6.49 -- 8.37E-11 73.9 0.05 15 ,35
2 
2.00E-15 
rs837323 13 101175664 PCCA T C 0.512 0.762 6.32 ++ 2.65E-10 35.6 0.213 160,14
2 
5.30E-16 
rs17382981 10 94953258 CYP26A1,MYOF T C 0.417 0.19 -6.31 -- 2.72E-10 67.9 0.077 155,33
2 
4.10E-07 
rs79266634 16 7309047 RBFOX1 C G 0.093 0.115 -5.93 -- 3.00E-09 0 0.561 156,26
8 
1.50E-08 








Table 1b Subset of the new loci harboring the smallest p-values for refractive error in the Stage 3 meta-analysis 8 














rs36024104 14 42294993 LRFN5 A G 0.823 NA 9.09 ++ 9.86E-20 15.9 0.01414 152,585 2.20E-12 
rs1556867 1 164213686 5S_rRNA, PBX1 T C 0.264 0.494 -8.81 -- 1.29E-18 71.1 0.06266 160,155 4.20E-17 
rs2225986 1 200311910 LINC00862 A T 0.381 0.169 -7.96 -- 1.68E-15 40.2 0.196 160,152 7.50E-17 
rs1207782 6 22059967 LINC00340 T C 0.577 0.265 -7.92 -- 2.47E-15 0 0.8946 160,149 4.90E-13 
rs72826094 10 114801488 TCF7L2 A T 0.799 0.838 7.88 ++ 3.20E-15 64.5 0.09323 156,825 4.90E-02 
rs297593 2 157363743 GPD2 T C 0.286 0.257 -7.82 -- 5.45E-15 0 0.5285 159,461 7.80E-11 
rs5442 12 6954864 GNB3 A G 0.068 NA -7.82 -- 5.48E-15 8.8 0.03693 146,217 1.20E-33 
rs10880855 12 46144855 ARID2 T C 0.507 0.464 -7.78 -- 7.35E-15 0 0.9683 160,144 4.80E-08 
rs2150458 21 47377296 PCBP3, COL6A1 A G 0.455 0.641 7.74 ++ 1.04E-14 55.7 0.1329 160,151 1.80E-13 
rs12898755 15 63574641 APH1B A G 0.245 0.456 7.53 ++ 4.98E-14 7.9 0.2974 159,506 1.40E-16 
rs7122817 11 117657679 DSCAML1 A G 0.507 0.662 7.51 ++ 5.73E-14 73.8 0.05077 160,147 1.10E-10 
rs10511652 9 18362865 SH3GL2, ADAMTSL1 A G 0.416 0.445 7.36 ++ 1.91E-13 44.8 0.1782 160,149 3.50E-18 
rs11101263 10 49414181 FRMPD2 T C 0.258 0.105 -7.33 -- 2.33E-13 0 0.3477 160,155 2.20E-13 
rs11118367 1 219790221 LYPLAL1 T C 0.482 0.630 -7.29 -- 3.16E-13 0 0.8576 160,141 1.20E-13 
rs9395623 6 50757699 TFAP2D, TFAP2B A T 0.315 0.381 7.25 ++ 4.16E-13 0 0.9579 160,151 2.20E-10 
rs284816 8 53362145 ST18, FAM150A A G 0.163 0.198 -7.21 -- 5.52E-13 0 0.9242 160,140 1.60E-08 
rs12965607 18 47391025 MYO5B T G 0.857 0.923 7.07 ++ 1.52E-12 20.8 0.01674 157,604 8.10E-16 
rs7747 4 80827062 ANTXR2 T C 0.202 0.093 7.03 ++ 2.05E-12 5.4 0.01267 150,327 7.70E-16 
rs12451582 17 54734643 NOG, C17orf67 A G 0.369 0.308 7.02 ++ 2.22E-12 0 0.5925 160,155 8.80E-18 
rs80253120 17 14138507 CDRT15 T C 0.626 0.723 6.97 ++ 3.25E-12 58.6 0.12 156,054 7.20E-11 
rs7968679 12 9313304 PZP A G 0.700 0.894 6.95 ++ 3.65E-12 0 0.01951 160,076 4.20E-10 
rs11202736 10 90142203 RNLS A T 0.717 0.762 -6.92 -- 4.53E-12 0 0.4007 160,150 9.40E-07 
rs72655575 8 60556509 SNORA51, CA8 A C 0.201 0.124 6.87 ++ 6.54E-12 0 0.8811 156,566 7.10E-07 
rs1790165 11 131928971 NTM A C 0.411 0.283 6.85 ++ 7.17E-12 0 0.003708 160,131 1.80E-10 
rs511217 11 30029948 METTL15, KCNA4 A T 0.738 0.729 -6.79 -- 1.10E-11 0 0.3626 160,143 1.40E-17 
 9 
We identified 140 loci for refractive error with genome-wide significance (P < 5 × 10−8) on the basis of the meta-analyses of the genome-wide 10 
single-variant linear regressions performed in 160,420 participants of mixed ancestries (CREAM-ASN, CREAM-EUR and 23andMe). Shown are 11 
the replication of the previously found loci from HapMap II and a subset of the new loci harboring the smallest P values. For each locus, 12 
represented by an index variant (the variant with smallest p-value in that locus), Effect Allele, Other Allele, effect allele frequencies per ancestry 13 
(EAF AZN and EAF EUR), effect size (Z-score), direction of the effect (Direction), the P value, heterogeneity I square (HetISq), heterogeneity P 14 
value (HetPval), Sample Size (N), and P value of the replication in UK Biobank are shown (Full table: Supplementary Table 2). Chr, 15 
chromosome; EAF, effect allele frequency; ASN, Asian; EUR, European; GWS, genome wide significant. 16 
3 
 
Table 2. Genetic correlation for refractive error between Europeans and East Asians 17 
Sample 1 Sample 2 Genetic effect 



















0.788 0.041 2.48E-07 0.865 0.054 0.014 
Abbreviations: EUR, European; EAS, East Asian. 
a P-value relates to a test of the null hypothesis that pge=1 or pgi=1. 
 18 
We calculated the genetic correlation of effect (pge) and impact (pgi) using Popcorn to compare the genetic associations between Europeans 19 
(CREAM-EUR, N= 44,192; 23andMe, N=104,292) and East Asians (CREAM-ASN, N= 9,826). Reference panels for Popcorn were constructed 20 
using genotype data for 503 EUR and 504 EAS individuals sequenced as part of the 1000 Genomes Project. SNPs used had a MAF of at least 5% 21 
in both populations, resulting in a final set of 3,625,602SNPs for the analyses using the 23andMe GWAS sample and 3,642,928 SNPs for those 22 
using the CREAM-EUR sample. These findings support a largely common genetic predisposition to refractive error and myopia in Europeans and 23 





All human research was approved by the relevant institutional review boards and conducted according 
to the Declaration of Helsinki. All CREAM participants provided written informed consent; all 
23andMe applicants provided informed consent online, and answered surveys according to 23andMe’s 
human subjects protocol, which was reviewed and approved by Ethical & Independent Review 
Services, an AAHRPP-accredited institutional review board. The UK Biobank received ethical 
approval from the National Health Service National Research Ethics Service (reference 11/NW/0382). 
Study data 
The study populations were participants of the Consortium for Refractive Error and Myopia 
(CREAM) comprising of 41,793 individuals with European ancestry from 26 cohorts (CREAM-EUR) 
and 11,935 individuals with Asian ancestry from 8 studies (CREAM-ASN); and customers of the 
23andMe genetic testing company who gave informed consent for inclusion in research studies 
consisting of 104,293 individuals (2 cohorts of individuals with European ancestry, N = 12,128 and N= 
92,165, respectively). All participants included in this analysis from CREAM and 23andMe were aged 
25 years or older. Participants with conditions that could alter refraction, such as cataract surgery, laser 
refractive procedures, retinal detachment surgery, keratoconus as well as ocular or systemic 
syndromes were excluded from the analyses. Recruitment and ascertainment strategies varied per 
study (Supplementary Table 1a,b, and Supplementary Note). Refractive error represented by 
measurements of refraction and analyzed as spherical equivalent (SphE =spherical refractive error + 
1/2 cylinder refractive error) was the outcome variable for CREAM; myopic refractive error 
represented by self-reported age of diagnosis of myopia (AODM) for 23andMe27. 
Genotype calling and imputation 
5 
 
Samples were genotyped on different platforms and study specific quality control measures of the 
genotyped variants were implemented before association analysis (Supplementary Table 1b). 
Genotypes were imputed using the appropriate ancestry-matched reference panel for all cohorts from 
the 1000 Genomes Project (Phase I version 3, March 2012 release) with either minimac100 or 
IMPUTE101. The metrics for pre-imputation quality control varied amongst studies, but genotype call 
rate thresholds were set at high level (≥0.95 for both CREAM and 23andMe). These metrics were 
similar to our previous GWAS analyses26,27; details per cohort can be found in Supplementary Table 
1b. 
GWAS per study  
For each CREAM cohort, a single marker analysis for the SphE (in diopters) phenotype was carried 
out using linear regression adjusting for age, sex and up to the first five principal components. All 
non-family-based cohorts removed one of each pair of relatives (after detection using either GCTA or 
IBS/IBD analysis). In family-based cohorts, a score test-based association was used to adjust for 
within-family relatedness102. For the 23andMe participants, Cox proportional hazards analysis testing 
AODM as the dependent variable were performed as previously described27, with P calculated using a 
likelihood ratio test for the single marker genotype term. We used an additive SNP allelic effect model 
for all analyses.  
 
Centralized quality control per study 
After individual GWAS, all studies underwent a second round of quality control (QC). Quantile-
quantile, effect allele frequency, P – Z test, standard error – sample size, and genomic control inflation 
factor plots were generated for each individual cohort using EasyQC103 (Supplementary Figure 2.1 ( 
Supplementary Figure 2.1.1 and 2.1.2), 2.2 (Supplementary Figure 2.2.1 – 2.2.5), 2.3 (Supplementary 






The GWAS meta-analyses were performed in three stages (Supplementary Figure 1). In Stage 1, 
European (CREAM-EUR, N=44,192) and Asian (CREAM-ASN, N=11,935) participants from the 
CREAM cohort were meta-analysed separately. Subsequently, all CREAM cohorts (CREAM-ALL) 
were meta-analysed. Variants with MAF < 1% or imputation quality score < 0.3 (info metric of 
IMPUTE) or Rsq < 0.3 (minimac) were excluded. A fixed effects inverse variance-weighted meta-
analysis was performed using METAL104. 1,063 variants clustering in 24 loci (Supplementary Table 2) 
were genome-wide significant (P=5.0x10-8). All 37 loci that were previously found by CREAM and 
23andMe using genotype data imputed to the HapMap II reference panel were replicated (pBonferroni 
1.85x10-3), and 36 of the 37 were genome-wide significant (Supplementary Table 2)26,27. In Stage 2, a 
meta-analysis of the two 23andMe cohorts (N23andMe_V2=12,128; N23andMe_V3=92,165) was performed, 
using similar filtering but a lower MAF threshold (< 0.5%). A total of 5,205 genome-wide significant 
variants clustered in 112 loci (Supplementary Table 2).  
In Stage 3, CREAM-ALL and 23andMe samples were combined using a fixed effects meta-
analysis based on P value and direction of effect. In all stages, each genetic variant had to be 
represented by at least half of the entire study population and at least represented by 13 cohorts in 
CREAM and one cohort in 23andMe. For SNPs with high heterogeneity (at P < 0.05), we also 
performed a random effects meta-analysis using METASOFT50. We chose a different weighting 
scheme due to the differences in effect size scaling; 23andMe used a less accurate phenotype variable 
(AODM); i.e. the effective sample size of the 23andMe was approximately equivalent to the effective 
sample size of CREAM-ALL (Figure 2b), thus weighting by (1/neffective) yielded a final weighting 
ratio of 1:1105. Genome-wide statistical significance was defined at P < 5.0 × 10-8 106.  
All three meta-analysis stages were performed under genomic control. Study specific and 
meta-analysis lambda (λ) estimates are shown in Supplementary Figure 6; to check for confounding 
biases (e.g. cryptic relatedness and population stratification), LD score intercepts from LD score 
regressions per ancestry were constructed (Supplementary Figure 7)30. To check the robustness of 
signals, we performed a conventional random effects models using METASOFT, fixed effects models 
7 
 
weighted on sample size and on weights estimated from standard error per allele tested using METAL 
(Supplementary Table 2 and Supplementary Table 3). 
Manhattan (modified version of package ‘qqman’), regional, box, and forest plots were made using R 
version 3.2.3 and LocusZoom107. An overview of the Hardy Weinberg P of all index variants per 
cohort can be found in Supplementary Table 4. The comparison between refractive error and age-of-
onset was performed using the LDSC program30.  
 
Population stratification and heritability calculations 
Each study assessed the degree of genetic admixture and stratification in their study participants 
through the use of principal components. Homogeneity of participants was assured by removal of all 
individuals whose ancestry did not match the prevailing ancestral group. We used genomic inflation 
factors to control for admixture and stratification, and performed genomic-controlled meta-analysis to 
account for the effects of any residual heterogeneity. To further distinguish between inflation from a 
true polygenic signal and population stratification, we examined the relationship between test statistics 
and linkage disequilibrium (LD) with LDSC. CREAM-EUR, CREAM-ASN and 23andMe were 
evaluated separately; variants not present in HapMap3 and MAF < 1% were excluded. SNP 
heritability estimates were calculated using LDSC for the same set of genetic variants. 
Locus definition and annotation 
All study effect size estimates were oriented to the positive strand of the NCBI Build 37 reference 
sequence of the human genome. The index variant of a locus was defined as the variant with the 
lowest P in a region spanning a 100 kb window of the most outer genome-wide significant variant of 
that same region. We annotated all index variants using the web-based version of ANNOVAR108 based 
on UCSC Known Gene Database35. For variants within the coding sequence or 5’ or 3’ untranslated 
regions of a gene, that gene was assigned to the index variant (note that this led to more than 1 gene 
being assigned to variants located within the transcription units of multiple, overlapping genes). For 
variants in intergenic regions, the nearest 5’ gene and the nearest 3’ gene were assigned to the variant. 
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Index variants were annotated to functional RNA elements when described as such in the UCSC 
Known Gene Database. We used conservation (PhyloP109) and prediction tools (SIFT39, Mutation 
Taster110, align GVGD40,41, PolyPhen-236) to predict the pathogenicity of protein-altering exonic 
variants.  
 
Conditional signal analysis 
 
We performed conditional analysis to identify additional independent signals nearby the index variant 
at each locus, using GCTA-COJO32. We transformed the Z-scores of the summary statistics to beta’s 
using the following formula: Standard Error = √1/2 ∗ 𝑁 ∗ 𝑀𝐴𝐹(1 − 𝑀𝐴𝐹) . We performed the 
GCTA-COJO analysis32, utilizing summary-level statistics from the meta-analysis on all cohorts. 
Linkage disequilibrium (LD) between variants was estimated from the Rotterdam Study I-III.  
 
Replication in UK Biobank  
The UK Biobank Eye & Vision (UKEV) Consortium performed a GWAS of refractive error in 95,505 
participants of European ancestry aged 37-73 year with no history of eye disorders33. Refractive error 
was measured using an autorefractor; SphE was calculated per eye and averaged between the two 
eyes. To account for relatedness a mixed model analysis with BOLT-LMM was used111, including age, 
gender, genotyping array, and the first 10 principal components as covariates. Analysis was restricted 
to markers present on the HRC reference panel112. We performed lookups for all independent genetic 
variants identified in our Stage 3 meta-analysis and conditional analysis. For 16 variants not present in 
UKEV, we performed lookups for a surrogate variant in high LD (r2 >0.8). When more than one 
potential surrogate variant was available, the variant in strongest LD with the index variant was 
selected. Six variants were not available for replication: one variant (rs188159083) was not present on 
the array nor was a surrogate available in UKEV and five variants showed evidence of departure from 
HWE (HWE exact test P<3.0x10-4). 
 
Post-GWAS analyses  
9 
 
We performed two gene-based tests to identify additional significant genes not found in the single 
variant analysis. First, we applied the gene-based test implemented in fastBAT42 to the per-variant 
summary statistics of the meta-analysis of all European cohorts (23andMe and CREAM-EUR). We 
used the default parameters (all variants in or within 50kb of a gene) and focused on variants with a 
gene-based P <2 x 10-6 (Bonferroni correction based on 25,000 genes) and the per-variant P >5 x 10-8. 
Secondly, we applied another gene-based test in EUGENE43 which only includes variants which are 
eQTLs (GTex, blood113). EUGENE tests an hypothesis predicated on eQTLs as key drivers of the 
association signal. eQTLs within 50kb of a gene were included in the test. Genes with EUGENE P <2 
x 10-6 (and not found in the single variant analysis) were considered to be significant. Finally, we used 
functional annotation information from genome-wide significant loci to reweigh results using fgwas 
(version 0.3.6444). Fgwas incorporates functional annotation (e.g. DNase I-hypersensitive sites in 
various tissues and 3’UTR regions) to reweight data from GWAS, and uses a Bayesian model to 
calculate a posterior probability of association. This approach is able to identify risk loci that 
otherwise might not reach the genome-wide significance threshold in standard GWAS. Details about 
this approach can be found in Supplementary Note.  
 
Refractive errors and myopia risk prediction 
To assess the risk of the entire range of refractive errors, we computed polygenic risk scores (PGRS) 
for the population-based Rotterdam Studies (RS) I, RS-II and RS-III using the P and Z scores from a 
meta-analysis on CREAM-ALL and 23andMe, excluding the RS I-III cohorts. Only variants with high 
imputation quality (IMPUTE info score > 0.5 or minimac Rsq > 0.8) and MAF > 1% were considered. 
P-based clumping was performed with PLINK114, using an r2 threshold of 0.2 and a physical distance 
threshold of 500 kb, excluding the MHC region. This resulted in a total of 243,938 variants. For each 
individual in RS-I, RS-II and RS-III (N = 10,792), PGRS were calculated using the --score command 
in PLINK across strata of P thresholds: 5.0 x 10-8, 5.0 x 10-7, 5.0 x 10-6, 5.0 x 10-5, 5.0 x 10-4, 0.005, 
0.01, 0.05, 0.1, 0.5, 0.8 and 1.0. The proportion of variance explained by each PGRS model was 
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calculated as the difference in the R2 between two regression models; one where SphE was regressed 
on age, sex, the first five principal components, and the other also including the PGRS as an additional 
covariate. Subsequently, AUCs were calculated for myopia (SphE ≤ -3 SD) versus hyperopia (SphE ≥ 
+3 SD). 
 
Genetic correlation between ancestries 
We used Popcorn48 to investigate ancestry-related differences in the genetic architecture of refractive 
error and myopia. Popcorn takes summary GWAS statistics from two populations and LD information 
from ancestry-matched reference panels, and computes genetic correlations by implementing a 
weighted likelihood function that accounts for the inflation of Z scores due to LD. Pairwise analyses 
were carried out using the GWAS summary statistics from 23andMe (N = 104,292), CREAM-EUR (N 
= 44,192) and CREAM-EAS (N = 9,826) meta-analyses. Only SNPs with MAF ≥ 5% were included, 
resulting in a final set of 3,625,602 SNPs for analyses involving 23andMe and 3,642,928 SNPs for the 
CREAM-EUR versus CREAM-EAS analysis. Reference panels were constructed using genotype data 
from 503 European and 504 East Asian individuals sequenced as part of the 1000 Genomes Project 
(release 2013-05-02 downloaded from: ftp.1000genomes.ebi.ac.uk). The reference panel VCF files 
were filtered using PLINK114 to remove indels, strand-ambiguous variants, variants without an “rs” id 
prefix, and variants located in the MHC region on chromosome 6 (chr6:25,000,000-33,500,000; Build 
37). 
  
Analysis between phenotypes 
To evaluate consistency of genotypic effects across studies that employed different phenotype 
definitions, we compared effect sizes from GWAS studies of either SphE or AODM in Europeans, i.e. 
CREAM-EUR (N = 44,192) or 23andMe (N = 104,293) respectively. Marker-wise additive genetic 
effect sizes (in units diopters per copy of the risk allele) for SphE were compared against those (in 
units log(HR) per copy of the risk allele) for AODM. Data was visualised using R. Genetic correlation 
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between the two phenotypes SphE and AODM was calculated using LD score regression. This 
analysis included all common SNPs (MAF > 0.01) present in HapMap3. 
 
Evidence for functional involvement 
In order to rank genes according to biological plausibility, we scored annotated genes based on our 
own findings and published reports for a potential functional role in refractive error. Points were 
assigned for each gene on the basis of 10 categories (details on the methodology per category are 
provided in Supplementary Note): internal replication of index genetic variants in the individual 
cohort GWAS analyses through Bonferroni corrections (CREAM-ASN, CREAM-EUR and 23andMe; 
pBonferroni 1.19 x 10-4), evidence for eQTL using the FUMA32 and extensive look-ups in GtEx, 
evidence of expression in the eye in developmental and adult ocular tissues, presence of an eye 
phenotype in knock-out mice (MGI and IMPC database), presence of an eye phenotype in humans 
(OMIM; see URLs, DisGeNET115), location in a functional region of a gene (wANNOVAR; see 
URLs), presence of the gene in a significant enriched functional pathway with false discovery rate < 
0.05 (DEPICT49), presence of the gene in the gene priority analysis of DEPICT with false discovery 
rate < 0.05 and the presence of the gene in the canonical pathway analysis of Ingenuity Pathway 
Analysis (IPA; See URLs). Furthermore, we performed a systematic search for each gene to assess its 
potential as a drug target (SuperTarget116, STITCH117, DrugBank118, PharmaGkb119). All information 
derived from this study and literature were used to annotate genes to retinal cell types. 
 
Genetic pleiotropy  
To investigate overlap of genes with other common traits, we performed a look-up in the GWAS 
catalog using FUMA. Multiple testing correction (i.e. Benjamini-Hochberg) was performed. Traits 
were significantly associated when adjusted P ≤ 0.05 and the number of genes that overlap with the 
GWAS catalog gene sets was ≥ 2.  
 
Data availability statement 
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The summary statistics of the Stage 3 meta-analysis are included in Supplementary Data 3 of this 
published article. In order to protect the privacy of the participants in our cohorts, further summary 
statistics of Stage 1 (CREAM) and Stage 2 (23andMe) will be available upon request. Please contact 
c.c.w.klaver@erasmusmc.nl (CREAM) and/or apply.research@23andMe.com (23andMe) for more 
information and to access the data.
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Supplementary Note  
1: Study Populations and Acknowledgements 
CREAM cohort 
CREAM (Consortium for Refractive Error and Myopia) was established in 2011 as a collaboration 
between studies with data on refractive error which had performed genome-wide association analysis 
based on SNP arrays. Details of each study cohort and their group-specific acknowledgements are 
provided below. 
1958 British Birth Cohort 
The 1958 British Birth Cohort1 is a prospective population-based cohort study that initially included 
17,000 newborn children whose birth was within the first week of March 1958. All participants gave 
informed written consent to participate in genetic association studies, and the study was approved by the 
South East Multi Centre Research Ethics Committee (MREC) and the Oversight Committee for the 
biomedical examination of the British 1958 British birth cohort. Biomedical examination protocols were 
approved by the South East MREC. 
1958 British Birth Cohort acknowledgements: Phenotyping was funded by the Medical Research 
Council's Health of the Public grant (PIs Power and Strachan); the genetic studies by the Wellcome Trust 
(083478 to J.S.R.); some of the analysis by the National Institute for Health Research as Specialist 
Biomedical Research Centres in Paediatrics and Ophthalmology, partnering respectively with Great 
Ormond Street and Moorfields Hospitals; with additional personal funding (P.M.C) by the Ulverscroft 
Vision Research Group. 
ALIENOR 
The Alienor study is a population-based study in residents of Bordeaux, France2. The 963 participants, 
aged 73 years or more, were recruited from an ongoing population-based study (3C Study)3. They 
underwent an ophthalmological examination, including a recording of ophthalmological history, measures 
of visual acuity, refraction, two 45° non mydriatic colour retinal photographs (one centred on the macula, 
the other centred on the optic disc), measures of intraocular pressure and central corneal thickness and 
break-up time test. Refraction was measured first using autorefractometer (Speedy K, Luneau, France) 
and secondly by measuring subjective measurement, which was used in the analysis. This research 
followed the tenets of the Declaration of Helsinki. Participants gave written consent for the participation 
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in the study. The design of this study has been approved by the Ethical Committee of Bordeaux (Comité 
de Protection des Personnes Sud-Ouest et Outre-Mer III) in May 2006. After exclusion of subjects 
operated for cataract and other eye procedures and diseases that could alter refraction, 618 subjects were 
available, among which 529 were genotyped at the French national centre for genotyping (CNG) using 
Illumina Human 610-Quad BeadChip. Among them, 509 individuals had good genotype QC (individuals 
of European ancestry, unrelated with other individuals, without discrepancy between clinical and genetic 
gender and with missingness < 5%) and had imputation data. In addition, 2 subjects had missing 
education data, leaving 507 subjects in the statistical analysis. Imputation was performed in two steps: 
prephasing with SHAPEIT2, followed by imputation with IMPUTE2 using 1000 Genomes(March 2012, 
MACGT1) as reference panel. SNPs were used in the imputation process if call rate > 98%, HWE p-value 
> 1 x 10-6 , MAF> 1%. Analysis was performed using Quicktest, with adjustment on age, gender, 
education, PC1 and PC2 and modelling of interaction between SNP and education, using robust variance 
estimates. No SNP exclusion was applied on imputed SNPs. 
ALIENOR acknowledgements: The Alienor study is supported by laboratoires Théa (Clermont-Ferrand, 
France). The Three-City study is conducted under a partnership agreement between the Institut National 
de la Santé et de la Recherche Médicale (INSERM), the University of Bordeaux and Sanofi-Aventis. The 
Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The Three-City 
study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Caisse Nationale de 
Solidarité pour l’Autonomie, Direction Générale de la Santé, MGEN, Institut de la Longévité, Conseils 
Régionaux d’Aquitaine et Bourgogne, Fondation de France, Ministry of Research-INSERM Programme 
“Cohortes et collections de données biologiques”, Agence Nationale de la Recherche ANR PNRA 2006 
and LongVie 2007, and the "Fondation Plan Alzheimer" (FCS 2009-2012). Laboratoires Théa 
participated in the design of the Alienor study, but none of the sponsors participated in the collection, 
management, statistical analysis and interpretation of the data, not in the preparation, review or approval 
of the present manuscript. 
ALSPAC (Avon Longitudinal Study of Parents and Children) 
The research adhered to the tenets of the Declaration of Helsinki. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. 
Pregnant women with an expected date of delivery between 1st April 1991 and 31st December 1992, 
resident in the former Avon health authority area in Southwest England, were eligible to participate in this 
birth cohort study. 14,541 women were recruited. Data collection has been via various methods including 
self-completion questionnaires sent to the mother, to her partner and after age 5 to the child; direct 
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assessments and interviews in a research clinic. As well as investigating the health and well-being of the 
of the children in the birth cohort, the health of the mothers is also an important area of investigation4,5. 
DNA has been extracted from blood samples collected as part of routine antenatal care, during attendance 
at ALSPAC research clinics, or from immortalized lymphoblastoid cell lines, for a total of 10,321 of the 
mothers. Please note that the study website contains details of all the data that is available through a fully 
searchable data dictionary: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/.  
 
ALSPAC acknowledgements: Core support for ALSPAC was provided by the UK Medical Research 
Council and Wellcome Trust (Grant 102215/2/13/2) and the University of Bristol; this research 
specifically was funded by Wellcome Trust ISSF Populations Pilot Award (508353/509506); C.W. is 
supported by an NIHR Fellowship (CDF-2009-02-35). We are extremely grateful to all the families who 
took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, 
which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, 
volunteers, managers, receptionists and nurses. 
AREDS 
The Age-Related Eye Disease Study (AREDS) was initially designed as a long-term multicenter, 
prospective study of the clinical course of age-related macular degeneration (AMD) and age-related 
cataract6,7. In addition to collecting natural history data, AREDS included a randomized clinical trial of 
high-dose vitamin and mineral supplements for AMD and a clinical trial of high-dose vitamin 
supplements for cataract6-8. Prior to study initiation, the protocol was approved by an independent data 
and safety monitoring committee and by the institutional review board for each clinical center. Written 
informed consent was obtained from all participants before enrollment in accordance with the Declaration 
of Helsinki. AREDS participants were 55 to 80 years of age at enrollment and had to be free of any illness 
or condition that would make long-term follow-up or compliance with study medications unlikely or 
difficult. On the basis of fundus photographs graded by a central reading center, best-corrected visual 
acuity and ophthalmologic evaluations, 4,757 participants were enrolled in one of several AMD 
categories, including persons with no AMD (control group). Visual acuity measurement of all participants 
was performed with the standard procedure developed for the Early Treatment of Diabetic Retinopathy 
Study (ETDRS). A refraction measurement was performed for participants at the randomization visit and 
each annual visit. For those who experience a decrease of 10 letters from baseline visual acuity, 
refractions were also conducted at the non-annual visits. Blood samples were collected at baseline and 
longitudinally as participants were send, and cell lines were established. DNA was extracted from cell 
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lines according to standard protocols. For the current analysis, 816 participants aged 60 and older were 
included from the AREDS 1a-1b population and 1506 from the AREDS 1c population. Refractive error 
measured by a refraction protocol at baseline enrollment into the AREDS study6-9 was analyzed, taking 
the mean measured spherical equivalent (SE) across both eyes (or SE in a single eye when both eyes were 
not measured) as the trait of interest. Age, gender and the first two principal components (to adjust for 
significant population stratification) were also included as covariates. 
Acknowledgements AREDS: AREDS1a1b and FECD were supported by the National Eye Institute 
(grants R01EY16482, R21EY015145, and P30EY11373) and by Research to Prevent Blindness and the 
Ohio Lions Eye Research Foundation. The investigators gratefully acknowledge the role of the clinical 
coordinators and investigators who collected data on FECD cases and controls. Individual investigators 
and sites are listed in the first publication of the FECD study10. Data for the AREDS1a and 1b studies was 
downloaded from dbGaP for analysis under a National Eye Institute data use agreement. 
AREDS1c was supported by contracts from National Eye Institute/National Institutes of Health, 
Bethesda, MD, with additional support from Bausch & Lomb Inc, Rochester, NY. The genotyping costs 
were supported by the National Eye Institute (R01EY020483 to D.S.) and some of the analyses were 
supported by the Intramural Research Program of the National Human Genome Research Institute, 
National Institutes of Health, USA. AREDS acknowledges Frederick Ferris, National Eye Institute, 
National Institutes of Health, Bethesda, MD; and the Center for Inherited Disease Research, Baltimore, 
MD where SNP genotyping was carried out. The investigators gratefully acknowledge the advice and 
guidance of Hemin Chin of the National Eye Institute. 
Blue Mountains Eye Study (BMES) 
The Blue Mountains Eye Study (BMES) is a population-based cohort of a predominantly white 
population in west of Sydney, Australia. At baseline (1992-94), 3,654 permanent residents aged 49 years 
or older participated (participation rate of 82.4%11. During 1997-99 (BMES II A), 2,335 participants 
(75.1% of survivors) returned for examinations after 5 years. During 1999-2000, 1,174 (85.2%) new 
participants took part in an Extension Study of the BMES (BMES IIB). BMES cross-section II thus 
includes BMES IIA (66.5%) and BMES IIB (33.5%) participants (n=3,509)12. From the BMES cross 
section II who had blood samples collected, DNA was extracted for 3,189 (90.1 %) participants. Over 
98% of BMES participants were European ancestry. All BMES examinations were approved by the 
Human Ethics Committees of the Western Sydney Area Health Service and University of Sydney. Signed 
informed consent was obtained from participants at each examination. 
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Acknowledgements BMES : BMES was supported by the Australian National Health & Medical Research 
Council (NH&MRC), Canberra Australia (974159, 211069, 457349, 512423, 475604, 529912); the 
Centre for Clinical Research Excellence in Translational Clinical Research in Eye Diseases; NH&MRC 
research fellowships (358702, 632909 to J.J.W, 1028444, 1138585  to P.N.B.); and the Wellcome Trust, 
UK as part of Wellcome Trust Case Control Consortium 2 (A. Viswanathan, P. McGuffin, P. Mitchell, F. 
Topouzis, P. Foster) for genotyping costs of the entire BMES population (085475B08Z, 08547508Z, 
076113). The Centre for Eye Research Australia receives Operational Infrastructure Support from the 
Victorian government. BMES acknowledges Jie Jin Wang and Elena Rochtchina from the Centre for 
Vision Research, Department of Ophthalmology and Westmead Millennium Institute University of 
Sydney (NSW Australia); John Attia, Rodney Scott, Elizabeth G. Holliday from the University of 
Newcastle (Newcastle, NSW Australia); Jing Xie from the Centre for Eye Research Australia, University 
of Melbourne; Michael T. Inouye, Medical Systems Biology, Department of Pathology & Department of 
Microbiology & Immunology, University of Melbourne (Victoria, Australia); Ananth Viswanathan, 
Moorfields Eye Hospital (London, UK); Paul J. Foster, NIHR Biomedical Research Centre for 
Ophthalmology, UCL Institute of Ophthalmology & Moorfields Eye Hospital (London); Peter McGuffin, 
MRC Social Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, King's 
College (London, United Kingdom); Fotis Topouzis, Department of Ophthalmology, School of Medicine, 
Aristotle University of Thessaloniki, AHEPA Hospital (Thessaloniki, Greece); Xueling Sim, National 
University of Singapore; members of the Wellcome Trust Case Control Consortium 2. 
 
CROATIA-Korčula Study 
The CROATIA-Korčula study, Croatia, is a population-based, cross-sectional study in the island of 
Korčula that includes a total of 969 adult examinees, aged 18-98 (mean=56.3), and most (N=930) 
underwent a complete eye examination13. The study received approval from relevant ethics committees in 
Scotland and Croatia and followed the tenets of the Declaration of Helsinki. 
CROATIA-Split Study 
The CROATIA-Split study, Croatia, is a population-based, cross-sectional study in the Dalmatian City of 
Split that includes 1000 examinees aged 18-95. The study received approval from relevant ethics 




The CROATIA-Vis study, Croatia, is a population-based, cross-sectional study in the island of Vis 
including adult participants, aged 18–93 years (mean = 56), a subset of which (N=640) underwent a 
complete eye examination in summer 2007 and provided their ophthalmologic history13. The study 
received approval from relevant ethics committees in Scotland and Croatia and followed the tenets of the 
Declaration of Helsinki. 
Acknowledgements CROATIA-Korčula, CROATIA-Split and CROATIA-Vis studies: The CROATIA 
studies were funded by grants from the Medical Research Council (UK), from the Republic of Croatia 
Ministry of Science, Education and Sports (108-1080315-0302; 216-1080315-0302) and the Croatian 
Science Foundation (8875); and the CROATIA-Korčula genotyping was funded by the European Union 
framework program 6 project EUROSPAN (LSHGCT2006018947). The CROATIA studies 
acknowledges Dr. Biljana Andrijević Derk, Valentina Lacmanović Lončar, Krešimir Mandić, Antonija 
Mandić, Ivan Škegro, Jasna Pavičić Astaloš, Ivana Merc, Miljenka Martinović, Petra Kralj, Tamara 
Knežević and Katja Barać-Juretić as well as the recruitment team from the Croatian Centre for Global 
Health, University of Split and the Institute of Anthropological Research in Zagreb for the 
ophthalmological data collection; Peter Lichner and the Helmholtz Zentrum Munchen (Munich, 
Germany), AROS Applied Biotechnology, Aarhus, Denmark and the Wellcome Trust Clinical facility 
(Edinburgh, United Kingdom) for SNP array genotyping; genetic analyses were supported by the MRC 
HGU “QTL in Health and Disease” core programme. 
Diabetes Control and Complications Trial (DCCT) 
DCCT (1982-1993) was a multi-center randomized clinical trial to compare the effectiveness of intensive 
(≥3 daily insulin injections or insulin pump) and conventional (<3 daily insulin injections) diabetic 
treatments at the time in preventing development and progression of microvascular complications of type 
1 diabetes. Subjective refraction was measured following the standard protocols using a letter chart at 10 
to 20 feet, at baseline visit and annually thereafter during DCCT. Refraction measurement was attempted 
at 1 meter for the subjects with poor visual acuity. In these cases the 4 meter refraction was estimated by 
subtracting +0.75 sphere from the 1 m measurement14. In the current study measurements at baseline were 
analyzed. 
 
Acknowledgements DCCT: A complete list of researchers in the DCCT/EDIC Research Group is 
presented in the Supplementary Material published online15. Industry contributors have had no role in the 
DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants’ 
adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes 
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Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), Eli Lilly 
(Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA) , LifeScan 
(Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Ft. Lauderdale, FL), 
Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche 
Diabetes Care (Indianapolis, IN) , and Sanofi-Aventis (Bridgewater, NJ). GWAS results from 
DCCT/EDIC will be made available through dbGaP. The DCCT/EDIC has been supported by 
cooperative agreement grants (1982-1993, 2012-2017), and contracts (1982-2012) with the Division of 
Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and 
Kidney Disease (current grant numbers U01 DK094176 and U01 DK094157), and through support by the 
National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical 
Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-
present), Bethesda, Maryland, USA. Trial Registration: clinicaltrials.gov NCT00360815 and 
NCT00360893. Additional support for this DCCT/EDIC collaborative study was provided by JDRF grant 
# 17-2013-9. 
Estonian Genome Center, University of Tartu (EGCUT) 
The Estonian cohort is from the population-based biobank of the Estonian Genome Center of the 
University of Tartu (EGCUT). The whole project is conducted according to the Estonian Gene Research 
Act and all participants have signed the broad informed consent (http://www.biobank.ee16). The current 
cohort size is over 51,515, from 18 years of age and up, which reflects closely the age distribution in the 
adult Estonian population. Subjects are recruited by the general practitioners (GP), physicians in the 
hospitals,and special recruitment offices of the EGCUT. They were randomly selected from the 
individuals visiting GP offices or hospitals. Computer Assisted Personal interviews were conducted by 
primary care providers and nurses during 1-2 hours at a doctor’s office to collect information that includes 
personal data (place of birth, place(s) of living, nationality etc.), genealogical data (family history, three 
generations), educational and occupational history and lifestyle data (physical activity, dietary habits, 
smoking, alcohol consumption, women’s health, quality of life) etc. Anthropometric and physiological 
measurements were also taken. All diseases are defined according to the ICD10 coding17.  
Acknowledgements EGCUT: EGCUT was supported by European Union H2020 grant 692145, Est.RC 
grant IUT20-60 and EU Project No. 2014-2020.4.01.15-0012. They received financing by FP7 grants 
(201413, 245536); Estonian Government (SF0180142s08); and the European Union through the 
European Regional Development Fund, in the frame of Centre of Excellence in Genomics and Estonian 
Research Infrastructure’s Roadmap; EFSD grant; and the University of Tartu (SP1GVARENG). EGCUT 





European Prospective Investigation into Cancer (EPIC-Norfolk) 
The European Prospective Investigation into Cancer (EPIC) study is a pan-European prospective cohort 
study designed to investigate the aetiology of major chronic diseases18. EPIC-Norfolk, one of the UK 
arms of EPIC, recruited and examined 25,639 participants aged 40-79 years between 1993 and 1997 for 
the baseline examination19. Recruitment was via general practices in the city of Norwich and the 
surrounding small towns and rural areas, and methods have been described in detail previously20. Since 
virtually all residents in the UK are registered with a general practitioner through the National Health 
Service, general practice lists serve as population registers. Ophthalmic assessment formed part of the 
third health examination and this has been termed the EPIC-Norfolk Eye Study21. In total, 8,623 
participants were seen for the ophthalmic examination, between 2004 and 2011. Refractive error was 
measured using a Humphrey Auto-Refractor 500 (Humphrey Instruments, San Leandro, California, 
USA). Genotyping was undertaken using the Affymetrix GeneChip Human Mapping 500K Array Set. 
Data were pre-phased with SHAPEIT version 2 and imputed to the March 2012 build of the 1000 
Genomes project using IMPUTE version 2.2.2. The EPIC-Norfolk Eye Study was carried out following 
the principles of the Declaration of Helsinki and the Research Governance Framework for Health and 
Social Care. The study was approved by the Norfolk Local Research Ethics Committee (05/Q0101/191) 
and East Norfolk & Waveney NHS Research Governance Committee (2005EC07L). All participants gave 
written, informed consent.  
Acknowledgements EPIC-Norfolk: EPIC-Norfolk infrastructure and core functions are supported by 
grants from the Medical Research Council (G1000143) and Cancer Research UK (C864/A14136). The 
clinic for the third health examination was funded by Research into Ageing (262). Mr Khawaja is a 
Wellcome Trust Clinical Research Fellow. Miss Chan is a joint Medical Research Council/Royal College 
of Ophthalmologists Research Fellow, and received additional support from the International Glaucoma 
Association. Professor Foster has received additional support from the Richard Desmond Charitable Trust 
(via Fight for Sight) and the Department for Health through the award made by the National Institute for 
Health Research to Moorfields Eye Hospital and the UCL Institute of Ophthalmology for a specialist 
Biomedical Research Centre for Ophthalmology. 
 
Erasmus Rucphen Family Study (ERF) 
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The Erasmus Rucphen Family (ERF) Study is a family-based cohort in a genetically isolated population 
in the southwest of the Netherlands with over 3,000 participants aged between 18 and 86 years. Cross-
sectional examination took place between 2002 and 2005. The rationale and study design of this study 
have been described elsewhere22,23. Cross-sectional examination took place between 2002 and 2005, 
including a non-dilated automated measurement of refractive error using a Topcon RM-A2000 
autorefractor. All measurements in these studies were conducted after the Medical Ethics Committee of 
the Erasmus University had approved the study protocols and all participants had given a written 
informed consent in accordance with the Declaration of Helsinki. 
 
Acknowledgements ERF: see Rotterdam Study. 
Fuchs’ Endothelial Corneal Dystrophy Controls (FECD) 
We utilized control subjects who were part of a larger study on the genetics of Fuchs’ Endothelial Corneal 
Dystrophy (FECD)10. All control subjects were of European descent and were at least 60 years of age and 
matched according to age, gender, and ancestry to the enrolled index cases. To qualify, each control 
subject was required to be grade 0 on the FECD grading scale, have no family history of a possibly 
inherited corneal disorder (eg, FECD, keratoconus, stromal dystrophy), and have normal corneas with no 
abnormalities on slit-lamp examination apart from certain conditions judged not to affect FECD10. 
Subjects were excluded from participation as controls if they displayed any signs of corneal dystrophy or 
degeneration or had previous/active interstitial keratitis or anterior uveitis, or active/previous infectious 
keratitis, or vascularization of the epithelium and/or stroma. Subjects were also excluded if they had 
previously undergone bilateral corneal surgery or had experienced perforating corneal trauma resulting in 
scarring. Measurements of refractive error, central corneal thickness and absence of FECD were obtained 
at baseline, along with recorded age, and gender. This work was performed in accordance with the tenets 
of the Declaration of Helsinki. Written informed consent was obtained from all participants. Data were 
collected under multi-center Institutional Review Board (IRB) approval. 
Acknowledgements FECD: see BMES 
Finnish Twin Study on Aging (FITSA) 
Finnish Twin Study on Aging (FITSA) is a study of genetic and environmental effects on the disablement 
process in older female twins24. The study cohort of 13 888 adult twin pairs started in 1975. Altogether 
103 MZ and 114 DZ twin pairs (424 individuals, all women of European ancestry) aged 63-76 years 
living in Finland took part in multiple laboratory examinations in 2000 and 2003, and responded in 
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questionnaires in 2011. Before the examinations, the subjects provided a written informed consent 
according to the Declaration of Helsinki. The study protocol was approved by the ethics committee of the 
Central Hospital District of Central Finland. 
Acknowledgements FITSA: FITSA was supported by ENGAGE (FP7-HEALTH-F4-2007, 201413); 
European Union through the GENOMEUTWIN project (QLG2-CT-2002-01254); the Academy of 
Finland Center of Excellence in Complex Disease Genetics (213506, 129680); the Academy of Finland 
Ageing Programme; and the Finnish Ministry of Culture and Education and University of Jyväskylä. For 
FITSA the contributions of Emmi Tikkanen, Samuli Ripatti, Markku Kauppinen, Taina Rantanen and 
Jaakko Kaprio are acknowledged. 
Framingham Eye Study 
The Framingham Eye Study25 (FES) was nested within the Framingham Heart Study (FHS, 
http://www.framinghamheartstudy.org), which began its first round of extensive physical examinations in 
1948 by recruiting 5,209 men and women from the town of Framingham, MA, USA. Surviving 
participants from the original cohort returned for biennial exams, which continue to the present. A total of 
2675 FHS participants were also examined as part of the FES between 1973 and 1975. The FES was 
designed to evaluate ocular characteristics of examinees such as: senile cataract; age-related macular 
disease; glaucoma; and retinopathy. Between 1989 and 1991, 1603 offspring of original cohort 
participants also received ocular examinations26. The analyses in the current study are limited 1497 
(42.5% men) participants from both the original and the offspring cohorts for whom genotype data were 
available. Most individuals in this analysis set are unrelated but a small number of related pairs remain. 
All data--including refractive error, demographics and genotypes--were retrieved from the database of 
Genotypes and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap) after approval for controlled 
access to individual-level data. All study protocols are in compliance with the World Medical Association 
Declaration of Helsinki. Since 1971, written consent has been obtained from participants before each 
examination. The research protocols of the Framingham Heart Study are reviewed annually by the 
Institutional Review Board of the Boston University Medical Center and by the Observational Studies 
Monitoring Board of the National Heart, Lung and Blood Institute. 
 
Acknowledgements Framingham Eye Study: Framingham Eye Study was supported by NEI 
(N01EY22112, N01EY92109); the National Heart, Lung, and Blood Institute (N02HL64278) for SHARe 
genotyping; Boston University (N01HC25195); and by intramural funds of the National Human Genome 
Research Institute, NIH, USA (to R.W. and J.E.B.W.). 
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Gutenberg Health Study (GHS1, GHS2) 
The Gutenberg Health Study is a population-based, prospective, observational cohort study in mid-
western Germany that includes consecutive follow-ups every five years. The primary study aim is to 
evaluate and improve cardiovascular risk stratification and the general health status of the population. The 
baseline examination included a total of 15,010 participants aged 35 to 74 years and took place from 2007 
to 2012. The participants were randomly drawn and equally stratified for sex, residence (urban or rural) 
and for each decade of age. Exclusion criteria were the following: insufficient knowledge of German and 
physical or mental inability to participate in the examinations in the study center. The ophthalmic 
examination was based on standard operating procedures and included without limitation autorefraction 
and visual acuity testing (Humphrey® Automated Refractor/Keratometer (HARK) 599™, Carl Zeiss 
Meditec AG, Jena, Germany). The study protocol and study documents were approved by the local ethics 
committee of the Medical Chamber of Rhineland-Palatinate, Germany (reference no. 837.020.07; original 
vote: 22.3.2007, latest update: 20.10.2015). According to the tenets of the Declaration of Helsinki, written 
informed consent was obtained from all participants prior to their entry into the study. 
 
Acknowledgements Gutenberg Health Study (GHS1, GHS2): The Gutenberg Health Study is funded 
through the government of Rhineland-Palatinate („Stiftung Rheinland-Pfalz für Innovation“, contract AZ 
961-386261/733), the research programs “Wissen schafft Zukunft” and “Center for Translational 
Vascular Biology (CTVB)” of the Johannes Gutenberg-University of Mainz, the National Genome 
Network ''NGFNplus'' by the Federal Ministry of Education and Research, Germany (A301GS0833) and 
its contract with Boehringer Ingelheim, PHILIPS Medical Systems and Novartis Pharma. We thank all 
study participants for their willingness to provide data for this research project and we are indebted to all 
coworkers for their enthusiastic commitment. 
 
KORA 
KORA ("Kooperative Gesundheitsforschung in der Region Augsburg" which translates as “Cooperative 
Health Research in the Region of Augsburg”) is a population based study of adults randomly selected 
from 430,000 inhabitants living in Augsburg and 16 surrounding counties in Germany27-29. The collection 
was done in 4 separate groups from 1984-2001 (S1-S4). All survey participants are residents of German 
nationality identified through the registration office. In the KORA S3 and S4 studies 4,856 and 4,261 
subjects have been examined implying response rates of 75% and 67%, respectively. 3,006 subjects 
participated in a 10-year follow-up examination of S3 in 2004/05 (KORA F3), and 3080 of S4 in 
2006/2008 (KORA F4). The age range of the participants was 25 to 74 years at recruitment. The study 
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was approved by the local ethics committee. Written informed consent was obtained from all participants 
before enrollment in accordance with the Declaration of Helsinki.  
Acknowledgements KORA: KORA was financed by the Helmholtz Center Munich, German Research 
Center for Environmental Health; the German Federal Ministry of Education and Research; the State of 
Bavaria; the German National Genome Research Network (NGFN-2 and NGFNPlus) (01GS0823); 
Munich Center of Health Sciences as part of LMUinnovativ; the genotyping was carried out by the Center 
for Inherited Disease Research, Baltimore, MD, and was supported by the National Eye Institute (R01 
EY020483 to D.S.). Some of the analyses were supported by the Intramural Research Program of the 
National Human Genome Research Insitute, NIH, USA. 
OGP Ogliastra Genetic Park, Talana study (OGP Talana) 
 
A cross-sectional ophthalmic study was performed in Talana, Perdasdefogu and Urzulei within the 
Ogliastra Project, a large epidemiological survey conducted in a geographically, culturally and genetically 
isolated population living in an eastern-central region of Sardinia30. In Talana the study was carried out 
between October 2001 and October 2002 and adhered to the tenets of the declaration of Helsinki. Talana 
is a village situated at an altitude of 700 m above sea level in one of the most secluded areas of Sardinia, 
Ogliastra; it has about 1200 inhabitants and, importantly, archival records are available from 1589 and 
genealogical trees have been reconstructed from 1640. 789 volunteers gave their written informed consent 
and were invited to the local medical centre, which was equipped with a complete set of ophthalmic 
instruments for this survey. Participants underwent a complete eye examination including visual acuity 
(Snellen charts, 5 m) and refraction status assessment (autorefractor RK-8100 Topcon, Tokyo, Japan) 
 
Acknowledgements OGP Ogliastra Genetic Park, Talana study (OGP Talana): OGP Talana was 
supported by grants from the Italian Ministry of Education, University and Research (5571DSPAR2002, 
718Ric2005). OGP Talana thanks the Ogliastra population and the municipal administrators for their 
collaboration to the project and for economic and logistic support. 
 
Orkney Complex Disease Study (ORCADES) 
The Orkney Complex Disease Study (ORCADES) is a population-based, cross-sectional study in the 
Scottish archipelago of Orkney, including 1,285 individuals with eye measurements. The study received 




Acknowledgements ORCADES: ORCADES recruitment and genotyping were supported by the Chief 
Scientist Office of the Scottish Government, the Royal Society, the UK Medical Research Council 
Human Genetics Unit and the European Union framework program 6 EUROSPAN project 
(LSHGCT2006018947). ORCADES acknowledges the invaluable contributions of Lorraine Anderson 
and the research nurses in Orkney, in particular Margaret Pratt who performed the eye measurements, as 
well as the administrative team in Edinburgh University, the Wellcome Trust Clinical facility (Edinburgh, 
United Kingdom) for DNA extraction, Peter Lichner and the Helmholtz Zentrum Munchen (Munich, 
Germany) for genotyping, and Mirna Kirin, Pau Navarro and Peter Joshi for the genetic data imputation. 
Genetic analyses were supported by the MRC HGU “QTL in Health and Disease” core programme. 
Rotterdam Study (RS1, RS2, RS3) 
The Rotterdam Study is a prospective population-based cohort study in the elderly living in Ommoord, a 
suburb of Rotterdam, the Netherlands. Details of the study are described elsewhere31. In brief, the 
Rotterdam Study consists of 3 independent cohorts: RS1, RS2, and RS3. For the current analysis, 5,328 
residents aged 55 years and older were included from RS1, 2,009 participants aged 55 and older from 
RS2, and 1,970 aged 45 and older from RS 3. 99% of subjects were of European ancestry. Participants 
underwent multiple physical examinations with regular intervals from 1991 to present, including a non-
dilated automated measurement of refractive error using a Topcon RM-A2000 autorefractor. All 
measurements in RS-1–3 were conducted after the Medical Ethics Committee of the Erasmus University 
had approved the study protocols and all participants had given a written informed consent in accordance 
with the Declaration of Helsinki. 
Acknowledgements Rotterdam Study and ERF: The Rotterdam Study and ERF were supported by 
European Research Council (ERC) under the European Union's Horizon 2020 research and innovation 
programme (grant 648268), Netherlands Organisation for Scientific Research (NWO, grant 91815655), 
Erasmus Medical Center and Erasmus University, Rotterdam, The Netherlands; Netherlands Organization 
for Health Research and Development (ZonMw); UitZicht; Netherlands Organisation for Scientific 
Research (NWO Veni 91617076 to V.J.M.V.); the Research Institute for Diseases in the Elderly; the 
Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European 
Commission (DG XII); the Municipality of Rotterdam; the Netherlands Genomics Initiative/NWO; 
Center for Medical Systems Biology of NGI; Lijf en Leven; M.D. Fonds; Henkes Stichting; Stichting 
Nederlands Oogheelkundig Onderzoek; Swart van Essen; Bevordering van Volkskracht; Blindenhulp; 
Landelijke Stichting voor Blinden en Slechtzienden; Rotterdamse Vereniging voor Blindenbelangen; 
Oogfonds; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting MaculaFonds; 
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Combined Ophthalmic Research Rotterdam; Rotterdamse Oogheelkundig Onderzoek Stichting; Erasmus 
MC Vriendenfonds, Topcon Europe; Novartis; Ada Hooghart, Corina Brussee, Riet Bernaerts-Biskop, 
Patricia van Hilten, Pascal Arp, Jeanette Vergeer, Marijn Verkerk; Sander Bervoets. 
TEST/BATS 
The Australian Twin Eye Study comprises participants examined as part of the Twins Eye Study in 
Tasmania or the Brisbane Adolescent Twins Study. Details of the study are described elsewhere32. Ethical 
approval was obtained from the Royal Victorian Eye and Ear Hospital, the University of Tasmania, the 
Australian Twin Registry and the Queensland Institute of Medical Research. 
 
Acknowledgements TEST/BATS: TEST and BATS (Australian Twins) were supported by an Australian 
National Health and Medical Research Council (NHMRC) Enabling Grant (2004-2009, 350415, 2005-
2007); Clifford Craig Medical Research Trust; Ophthalmic Research Institute of Australia; American 
Health Assistance Foundation; Peggy and Leslie Cranbourne Foundation; Foundation for Children; Jack 
Brockhoff Foundation; National Institutes of Health/National Eye Institute (RO1EY01824601 (2007-
2010)); Pfizer Australia Senior Research Fellowship (to D.A.M.); and Australian NHMRC Career 
Development Award (to S.M.). Genotyping was funded by an NHMRC Medical Genomics Grant; US 
National Institutes of Health/National Eye Institute (1RO1EY018246), Australian sample imputation 
analyses were carried out on the Genetic Cluster Computer which is financially supported by the 
Netherlands Scientific Organization (NWO48005003). Australian Twins thanks Grant Montgomery, Scott 
Gordon, Dale Nyholt, Sarah Medland, Brian McEvoy, Margaret Wright, Anjali Henders, Megan 
Campbell for ascertaining and processing genotyping data; Jane MacKinnon, Shayne Brown, Lisa 
Kearns, Jonathan Ruddle, Paul Sanfilippo, Sandra Staffieri, Olivia Bigault, Colleen Wilkinson, Yaling 
Ma, Julie Barbour for assisting with clinical examinations; and Dr Camilla Day and staff at the Center for 
Inherited Disease Research. 
TwinsUK 
The TwinsUK adult twin registry based at St. Thomas’ Hospital in London is a volunteer cohort of over 
10,000 twins from the general population33. Twins largely volunteered unaware of the eye studies, gave 
fully informed consent under a protocol reviewed by the St. Thomas’ Hospital Local Research Ethics 
Committee. 
Acknowledgements TwinsUK: TwinsUK received funding from the Wellcome Trust; the European Union 
MyEuropia Marie Curie Research Training Network; Guide Dogs for the Blind Association; the European 
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Community’s FP7 (HEALTHF22008201865GEFOS); ENGAGE (HEALTHF42007201413); the FP-5 
GenomEUtwin Project (QLG2CT200201254); US National Institutes of Health/National Eye Institute 
(1RO1EY018246); NIH Center for Inherited Disease Research; the National Institute for Health Research 
comprehensive Biomedical Research Centre award to Guy’s and St. Thomas’ National Health Service 
Foundation Trust partnering with King’s College London. P.G.H. is the recipient of a Fight for Sight ECI 
award. We acknowledge the contribution of Drs Toby Andrew, Margarida Lopes, Samantha Fahy and 
Diana Kozareva. 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) 
WESDR is an observational cohort study of diabetes complications (1979-2007)34. Subjective refraction, 
measured following standard protocols at first visit, was analyzed in the current study (n=589). 
Acknowledgements WESDR: WESDR was supported by NEI (grants R01EY03083 and EY016379) and a 
Research to Prevent Blindness Senior Scientific Investigator Award. 
Young Finns Study (YFS) 
The YFS cohort is a Finnish longitudinal population study sample on the evolution of cardiovascular risk 
factors from childhood to adulthood35. The first cross-sectional study was conducted in the year 1980 in 
five different centers. It included 3,596 participants in the age groups of 3, 6, 9, 12, 15, and 18, who were 
randomly chosen from the national population register. After the baseline in 1980 these subjects have 
been re-examined in 1983 and 1986 as young individuals, and in 2001, 2007 and 2011 as older 
individuals. For the current analysis a subsample from the newest (2011) follow-up was used from four 
centers (N=1479) where the refractive error measurements data from both eyes were available. 
This study was carried out in accordance with the recommendations of the Declaration of Helsinki. All 
participants provided written informed consent and the study protocol was approved by the Ethics 
Committee. 
 
Acknowledgements Young Finns Study (YFS): The Young Finns Study has been financially supported by 
the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 
(Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research 
Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant 
X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular 
Research ; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; 
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Yrjö Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; and Diabetes Research Foundation of 
Finnish Diabetes Association. 
 
Beijing Eye Study (BES) 
The BES is a population-based cohort of Han Chinese in the rural region and in the urban region of 
Beijing in North China. The Medical Ethics Committee of the Beijing Tongren Hospital approved the 
study protocol and all participants gave informed consent, according to the Declaration of Helsinki. At 
baseline (2001), 4439 individuals out of 5324 eligible individuals aged 40 years or older participated 
(response rate: 83.4%). In the years 2006 and 2011, the study was repeated by re-inviting all participants 
from the survey from 2001 to be re-examined. Out of the 4439 subjects examined in 2001, 3251 (73.2%) 
subjects returned for the follow-up examination in 2006, and 2695 (60.7%) subjects returned for the 
follow-up examination in 2011.  
Acknowledgements Beijing Eye Study: Beijing Eye Study was supported by National Natural Science 
Foundation of China (grant 81170890). 
Nagahama 
Nagahama Prospective Cohort for Comprehensive Human Bioscience (the Nagahama Study) is a 
community-based cohort consisted of 9,804 healthy Japanese volunteers recruited between 2008 and 2010 
from the general population of Nagahama City in Japan. Community residents from 30–74 years of age, 
living independently and without physical impairment or dysfunction were eligible. The Kyoto University 
Graduate School and Faculty of Medicine Ethics Committee and the Nagahama Municipal Review Board 
of Personal Information Protection approved the study protocol and procedures used to obtain informed 
consent. All the study procedures adhered to the tenets of the Declaration of Helsinki. All participants 
were fully informed about the purpose and procedures of the study, and written consent was obtained 
from each subject. 
Acknowledgements Nagahama: Nagaham Study was financially supported by Comprehensive Research 
on Aging and Health Science Research Grants for Dementia R&D from Japan Agency for Medical 
Research and Development (AMED) and the Centre of Innovation Program, the Global University Project 




All Singapore studies adhere to the Declaration of Helsinki. Ethics approvals have been obtained from the 
Institutional Review Boards of the Singapore Eye Research Institute, Singapore General hospital, 
National University of Singapore and National Healthcare Group, Singapore. In all cohorts, participants 
provided written, informed consent at the recruitment into the studies. 
Singapore Prospective Study Program (SP2) 
Samples of SP2 were from a revisit of two previously conducted population-based surveys carried out in 
Singapore between 1992 and 1998, including the National Health Survey 1992 and the National Health 
Survey 199836. These studies comprise random samplings of individuals stratified by ancestry from the 
entire Singapore population. A total of 8266 subjects were invited in this follow-up survey and 6301 
(76.1% response rate) subjects completed the questionnaire, of which 4056 (64.4% of those who 
completed the questionnaire) also attended the health examination and donated blood specimens. 
Acknowledgements Singapore Prospective Study Program (SP2): See “Acknowledgements Singapore 
Studies” 
Singapore Malay Eye Study (SiMES) 
SiMES is a population-based prevalence survey of Malay adults aged 40 to 79 years living in Singapore 
that was conducted between August of 2004 and June of 200637. From a Ministry of Home Affairs 
random sample of 16,069 Malay adults in the Southwestern area, an age-stratified random sampling 
strategy was used in selecting 1400 from each decade from age 40 years onward (40–49, 50–59, 60–69, 
and 70–79 years).The 4,168 eligible participants from the sampling frame, while 3280 (78.7%) 
participated. 
Acknowledgements Singapore Malay Eye Study (SiMES): See “Acknowledgements Singapore Studies” 
Singapore Indian Eye Study (SINDI) 
SINDI is a population-based survey of major eye diseases38 in ethnic Indians aged 40 to 80 years living in 
the South-Western part of Singapore and was conducted from August 2007 to December 2009. In brief, 
4,497 Indian adults were eligible and 3,400 participated. 
Acknowledgements Singapore Indian Eye Study (SINDI): See “Acknowledgements Singapore Studies” 
 
Singapore Chinese Eye Study (SCES) 
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Similar to SINDI, the Singapore Chinese Eye Study (SCES) is a population-based cross-sectional study of 
eye diseases in Chinese adults 40 years of age or older residing in the southwestern part of Singapore. The 
methodology of the SCES study has been described in details previously. Between 2009 and 2011, 3,353 
(72.8%) of 4,605 eligible individuals underwent a comprehensive ophthalmologic examination, using the 
same protocol as SINDI37. 
 
Acknowledgements Singapore Chinese Eye Study (SCES): see ”Acknowledgements Singapore Studies” 
STARS 
 
Acknowledgements Singapore Studies: The Singapore studies (SP2, SIMES, SINDI, SCES, STARS) 
were supported by the National Medical Research Council, Singapore (NMRC 0796/2003, NMRC 
1176/2008, STaR/0003/2008; CG/SERI/2010), Biomedical Research Council, Singapore (06/1/21/19/466, 
09/1/35/19/616 and 08/1/35/19/550). The Singapore Tissue Network and the Genome Institute of 
Singapore, Agency for Science, Technology and Research, Singapore provided services. National 
supercomputing centre (NSCC) provided high performance computing resources to support GWAS 
analysis. 
 
Acknowledgements UK Biobank: This research was facilitated by data from the UK Biobank Resource. 
UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council (UK), 
Department of Health (UK), Scottish Government, and Northwest Regional Development Agency.  It also 
had funding from the Welsh Assembly Government, British Heart Foundation, and Diabetes UK. The eye 
and vision dataset has been developed with additional funding from The NIHR Biomedical Research 
Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, Fight for Sight charity (UK), 
Moorfields Eye Charity (UK), The Macula Society (UK), The International Glaucoma Association (UK) 
and Alcon Research Institute (USA). This research has been conducted using the UK Biobank Resource 
(applications #17351 and #17615). 
 
Acknowledgements expression study Young TL et al: This study was funded by the National Institutes of 
Health R01 EY014685, the Research to Prevent Blindness Inc. Lew R. Wasserman Award,  and the 




2: methods per subfields of prioritization 
 
Internal replication of index genetic variants in the individual cohort GWAS’es (CREAM-ASN, 
CREAM-EUR and 23andMe) 
Internal replication of the index genetic variants from Stage 3 were checked in Stage 1 and 2 using the 
Bonferroni corrected p-value of 0.05/(140*3) = 1.19x10-4.  
 
Evidence for eQTL 
We used FUMA39 for eQTL look-ups which was based on eQTLs and gene expression used in the 
pipeline were obtained from GTEx v640, eQTLs of blood cells from the Blood eQTL Browser41 (cis-
eQTLs with FDR ≤ 0.05), eQTLs of blood cells in Dutch population from the BIOS QTL Browser (cis-
eQTLs on gene-level with FDR ≤ 0.05), eQTLs of 10 brain regions from BRAINEAC 
((http://www.braineac.org/,; sis-eQTLs with nominal P value < 0.05) and additional extensive look-ups in 
GtEx.  
 
Evidence of expression in the eye in developmental and adult ocular tissues 
Bergen AA et al:  
Gene expression of myopia candidate genes in laser dissected, freshy frozen retinal tissues: human  RPE, 
photoreceptors and choroid. Cellular expression was measured  using validated  44K microarray data on 
an Agilent platform in multiple samples,  and RNA levels were ranked in percentiles, with 100,00 
indicating the highest expression, and 0 the lowest, according to methodology described by  Booij et al 
(2009).  
Young TL et al: 
Expression of genes annotated to the index variants was studied in human ocular tissue using various 
methods: expression profiles in laser dissected freshly frozen RPE, photoreceptors and choroid of healthy 
human adult donor eyes42; whole-transcriptome expression analysis of macular and peripheral retina, 
choroid, and sclera from eight adult normal human ocular eyes43; and whole genome expression in retina, 
retinal pigment epithelium, choroid, sclera, optic nerve, and cornea from 15 normal fetal (24 weeks 
gestational age) and 6 adult donor eyes44. Human fetal and adult gene expression data for retina, RPE, 
choroid, sclera, optic nerve and cornea were obtained as described in Young TL, et al. (2013)44. In brief, 9 
fetal eyes at 12-weeks’ gestation and 6 fetal eyes at 24-weeks’ gestation were obtained from Advanced 
Biosciences Resources (Alameda, CA, USA), while 6 adult eyes were obtained from the North Carolina 
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Eye Bank (Winston–Salem, North Carolina, USA). Whole globes with a 2mm equatorial incision were 
immersed in RNAlater (Qiagen, Hilden, Germany) shortly after collection to preserve RNA integrity, and 
shipped overnight on ice. The retina, RPE, choroid and scleral tissues were isolated at the posterior pole 
using round biopsy punches. Some fetal tissues, such as RPE and retina could not be separated, and were 
collected in combination. Central corneal samples were isolated using a biopsy punch, and optic nerve 
was collected using clean dissection scissors. Tissue samples were homogenized at 4°C in Ambion lysis 
buffer using a Bead Ruptor Tissue Homogenizer (Omni, Kennesaw, Georgia, USA) with 2.38 mm metal 
beads, and RNA was extracted using the mirVanaTM total RNA extraction kit (Ambion, Austin, Texas, 
USA) following the manufacturer's protocol. The RNA samples were labeled and amplified using the 
Illumina Total Prep kit (Ambion, Austin, Texas, USA), and hybridized to Illumina HumanHT-12 v4 
Expression BeadChips (San Diego, California, USA). All protocols were performed following the 
manufacturer's recommendations. Twelve tissue samples were processed on each chip. Microarray data 
background noise was subtracted from the intensity values using Illumina’s GenomeStudio software, 
exported and log2 transformed. 
 
Presence of an eye phenotype in knock-out mice 
The Mouse Genome Informatics database (MGI, www.informatics.jax.org) and the International Mouse 
Phenotyping Consortium (IMPC, http://www.mousephenotype.org) were checked for entries matching an 
eye-phenotype. Genes were listed and their human equivalents were looked up in NCBI 
(www.ncbi.nlm.nih.gov). 
 
Presence of an eye phenotype in humans 
All genes were checked in Online Mendelian Inheritance in Man (OMIM, http://omim.org) and 
DisGeNET (http://www.disgenet.org) for the involvement of a human ocular phenotype. 
 
Presence of gene in a significant enriched functional pathway (DEPICT) 
We first clumped the SNPs with p-value <1x10-5 or lower from the meta-analysis of stage III using 500kb 
as physical distance threshold and an R2 > 0.1 with PLINK, resulting in 534 clumps. Secondly, we 
performed gene set, cell type, and tissue enrichment analyses using DEPICT45. The Affinity Propagation 
tool46-49 was used for clustering, and clusters were named by their ‘representative’ gene set, which was 
automatically chosen by the Affinity Propagation clustering method. The pairwise Pearson correlation 
between significant gene sets was calculated and then the AP algorithm was used to cluster similar 
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pathways into meta gene sets. Clusters were named by their representative gene set, which was 
automatically selected by the AP algorithm. In addition, correlation between the meta gene sets was 
calculated to create a network. The visualizations of the gene set enrichment analysis were created in 
Cytoscape50.  
 
Presence of gene in a significant canonical pathway (IPA) 
IPA is a subscription based manually curated knowledge archive. Bioinformatic analysis according to 
Ingenuity protocol and data sets containing RefSeq identifiers were uploaded into the application IPA. 
Each RefSeq identifier was mapped to its corresponding human splicing variant in the Ingenuity® 
Knowledge Base. Canonical pathway analysis identified the 5 canonical pathways from the IPA library 
that were most significant to the data set. The significance of the association between the data set and the 
canonical pathway was measured in two ways: 1) A ratio of the number of molecules from the data set 
that map to the pathway divided by the total number of molecules that map to the canonical pathway. 2) 
Fisher's Exact test was used to calculate a P-value determining the probability that the association 




3: Dopamine pathway look-ups   
To further investigate the association of genes playing a key role in the dopamine pathway, we we looked 
up the regions coding for dopamine receptors (DRD1, DRD2, DRD3, DRD4, DRD5), genes involved in 
synthesis & degradation (COMT, DBH, DDC, MAOA, TH) and transporters: (SLC6A3/DAT, 
SLC6A4/SERT) in the Stage 3 meta-analysis51-53. An overview of the results are provided in 




4: Phenotyping in CREAM and 23andMe  
 
CREAM 
Phenotyping of the CREAM cohorts has been described in detail previously54. Eligible participants 
underwent a complete ophthalmic examination, including a non-dilated measurement of refractive error 
for both eyes using a similar protocol (Supplementary Excel Table 1a). Inclusion criteria were individuals 
over the age of 25 years, of European or Asian descent, with available data on refractive error and with 
available genotype data. As previously described54, exclusion criteria were all refraction altering 
conditions and ocular syndromes or systemic syndromes. Spherical equivalent (SE) was calculated 
according to the standard formula (SE = sphere + ½ cylinder); the mean SE of two eyes was used for 
analyses. When SE was only available for one eye, the SE of this eye was used. 
 
23andMe 
All participants were drawn from the customer database of 23andMe, Inc., a direct-to-consumer genetic 
testing company. Phenotyping of this cohort has been described in detail previously55,56. Participants were 
asked online whether they had myopia (yes or no), and at what age they were diagnosed with myopia. 
Inclusion criteria were individuals of European ancestry, age at diagnosis between five and 30 years of 
age, and available genotype data.  
Participants provided informed consent and participated in the research online, under a protocol approved 





5: Gene-based test - fgwas 
We looked at enrichment of 450 genomic annotations as implemented in fgwas with 5000 SNPs per 
window and . We derived the best annotations from genome-wide significant loci. We first considered 
annotations separately to see if they were individually significant. Some annotations were correlated and, 
hence, we built a model by adding terms sequentially in decreasing order of significance. We started with 
a model with two region based annotations (top one third of the distribution of gene density and bottom 
one third of the distribution of gene density). We then added two SNP based annotations (SNPs between 
0 and 5kb from the transcription start site and SNPs between 5kb and 10kb from the transcription start 
site) and continued to add annotations until a maximum of 10 SNP based annotations were included in the 
model (adding further annotations is possible although we had problems with convergence within the 
fgwas software when a large number of annotations were added so we stopped adding further annotations 
at 10). We then applied the cross-validation approach implemented in fgwas to ensure no over-fitting in 
the final model. We used this final Bayesian model to derive a prior distribution for the remainder of the 
genome. We calculated the posterior probability of association based on the derived prior distribution. A 
posterior probability greater than 0.9 in this approach performed similarly to the traditional genome-wide 
significance threshold in genome-wide association studies (p-value<5 x 10-8) based on the analysis of 




Supplementary Figure 1: Study design flow-chart 
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Supplementary Figure 2.1: EasyQC plots per cohort – CREAM-ASN 
 
Supplementary Figure 2.1.1: Quality control – Quantile-Quantile (QQ), Pvalue-Z-statistics (P-Z) 
and Allele Frequency (AF)-plots per cohort in CREAM-ASN generated from EasyQC 
Panel 1: QQ-plots per cohort in CREAM-ASN; Panel 2: P-Z plots per cohort in CREAM-ASN; Panel 3: 
AF plots per cohort in CREAM-ASN; A=BES (n=590), B=Nagahama (n=2730); C=SCES (n=1724), 






Supplementary Figure 2.1.2: Lambda-N and SE-N plots per cohort in CREAM-ASN generated from EasyQC 
A=BES (n=590), B=Nagahama (n=2730); C=SCES (n=1724), D=SIMES (n=2275), E=SINDI (n=2110), F=STARS (n=817), G=SP2-610 





Supplementary Figures 2.2: EasyQC plots per cohort – CREAM-EUR  
 
 
Supplementary Figure 2.2.1: QQ-plots per cohort in CREAM-EUR generated from EasyQC 
A=EPIC (n=1084), B=ERF (n=2610), C=GHS1 (n=2738), D=GHS2 (n=1140), E=RSI (n=5787), F=RSII 
(n=2038), G=RSIII (n=2950), H=1958BBC (n=1658), I=ALIENOR (n=509), J=ANZRAG (n=648), 
K=ALSPAC (1865), L=CROATIA-KORCULA (n=822), M=CROATIA-SPLIT (n = 344), 
N=CROATIA-VIS (n=527), O=WESDR (n=295), P=EGCUT (n=904), Q=KORAF (n=2372), R=DCCT 
(n=791), S=OGP (n=509), T=TWINSUK (n=4342), U=YFS (n=1480), V=FITSA (n=329), W=AREDS 
(n=1842), X=FRAM (n=2729), Y=FECD (n=393), Z=TEST (n=267), AA=ORCADES (n=1165), 








Supplementary Figure 2.2.2: PZ-plots per cohort in CREAM-EUR generated from EasyQC 
A=EPIC (n=1084), B=ERF (n=2610), C=GHS1 (n=2738), D=GHS2 (n=1140), E=RSI (n=5787), F=RSII 
(n=2038), G=RSIII (n=2950), H=1958BBC (n=1658), I=ALIENOR (n=509), J=ANZRAG (n=648), 
K=ALSPAC (1865), L=CROATIA-KORCULA (n=822), M=CROATIA-SPLIT (n = 344), 
N=CROATIA-VIS (n=527), O=WESDR (n=295), P=EGCUT (n=904), Q=KORAF (n=2372), R=DCCT 
(n=791), S=OGP (n=509), T=TWINSUK (n=4342), U=YFS (n=1480), V=FITSA (n=329), W=AREDS 
(n=1842), X=FRAM (n=2729), Y=FECD (n=393), Z=TEST (n=267), AA=ORCADES (n=1165), 





Supplementary Figure 2.2.3: AF-plots per cohort in CREAM-EUR generated from EasyQC 
A=EPIC (n=1084), B=ERF (n=2610), C=GHS1 (n=2738), D=GHS2 (n=1140), E=RSI (n=5787), F=RSII 
(n=2038), G=RSIII (n=2950), H=1958BBC (n=1658), I=ALIENOR (n=509), J=ANZRAG (n=648), 
K=ALSPAC (1865), L=CROATIA-KORCULA (n=822), M=CROATIA-SPLIT (n = 344), 
N=CROATIA-VIS (n=527), O=WESDR (n=295), P=EGCUT (n=904), Q=KORAF (n=2372), R=DCCT 
(n=791), S=OGP (n=509), T=TWINSUK (n=4342), U=YFS (n=1480), V=FITSA (n=329), W=AREDS 
(n=1842), X=FRAM (n=2729), Y=FECD (n=393), Z=TEST (n=267), AA=ORCADES (n=1165), 





Supplementary Figure 2.2.4: Lambda-N plot of cohorts in CREAM-EUR generated from EasyQC 
A=EPIC (n=1084), B=ERF (n=2610), C=GHS1 (n=2738), D=GHS2 (n=1140), E=RSI (n=5787), F=RSII 
(n=2038), G=RSIII (n=2950), H=1958BBC (n=1658), I=ALIENOR (n=509), J=ANZRAG (n=648), 
K=ALSPAC (1865), L=CROATIA-KORCULA (n=822), M=CROATIA-SPLIT (n = 344), 
N=CROATIA-VIS (n=527), O=WESDR (n=295), P=EGCUT (n=904), Q=KORAF (n=2372), R=DCCT 
(n=791), S=OGP (n=509), T=TWINSUK (n=4342), U=YFS (n=1480), V=FITSA (n=329), W=AREDS 
(n=1842), X=FRAM (n=2729), Y=FECD (n=393), Z=TEST (n=267), AA=ORCADES (n=1165), 







Supplementary Figure 2.2.5: SE-N plot of cohorts in CREAM-EUR generated from EasyQC 
A=EPIC (n=1084), B=ERF (n=2610), C=GHS1 (n=2738), D=GHS2 (n=1140), E=RSI (n=5787), F=RSII 
(n=2038), G=RSIII (n=2950), H=1958BBC (n=1658), I=ALIENOR (n=509), J=ANZRAG (n=648), 
K=ALSPAC (1865), L=CROATIA-KORCULA (n=822), M=CROATIA-SPLIT (n = 344), 
N=CROATIA-VIS (n=527), O=WESDR (n=295), P=EGCUT (n=904), Q=KORAF (n=2372), R=DCCT 
(n=791), S=OGP (n=509), T=TWINSUK (n=4342), U=YFS (n=1480), V=FITSA (n=329), W=AREDS 
(n=1842), X=FRAM (n=2729), Y=FECD (n=393), Z=TEST (n=267), AA=ORCADES (n=1165), 




Supplementary Figure 2.3: EasyQC plots per cohort – 23andMe 
 
Supplementary Figure 2.3.1: Quality control – QQ, P-Z, AF-plots per cohort in 23andMe generated 
from EasyQC 
Panel 1: QQ-plots per cohort in 23andMe; Panel 2: P-Z plots per cohort in 23andMe; Panel 3: AF plots 





Supplementary Figure 2.3.2: Lambda-N and SE-N plots per cohort in 23andMe generated from 
EasyQC 
A=23andMe_V2 (n=12128), B=23andMe_V3 (n=92165).
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Supplementary Figure 3: Boxplots of effect sizes per cohort 
 
Tukey style box plots of the effect sizes of the 167 independent genetic variants associated with refractive 
error and myopia derived from the meta-analysis of stage 3 (n=160,420). The bottom and top of the box 
depict the first and third quartiles, the band is the median and the whiskers extend to the lowest and 










Supplementary Figure 4: Imputation Quality of genetic variants of Stage 3 































Imputation quality per MAF computed in R (ggplot2) 
A) Overall imputation quality (r2) of the 167 genetic variants before filtering (i.e. r2 > 0.3 and MAF  < 
0.01 CREAM or < 0.001 23andMe) of the stage 3 meta-analysis of all cohorts using an Illumina or 
Affymetrix platform, plotted against the minor allele frequency (MAF).  B) r2 of the 167 genetic variants 
before filtering of the stage 3 meta-analysis comparing all European cohorts and Asian, plotted against the 
minor allele frequency (MAF). C) r2 of the 167 genetic variants before filtering of the stage 3 meta-
analysis of all participating cohorts. D) r2 of the 167 genetic variants before filtering of the stage 3 meta-
analysis based on type of array used. Bands indicate the 95% confidence intervals; nstudies: number of 
cohorts; nsample: number of participants tested. 
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Shown are the Manhattan plots and QQ plots depicting P values for association of the meta-analysis of Stage 1. 
CREAM-EUR (nsample= 44,192 participants; ngenetic variants =9.6M); λgenomic inflation = 1.119. CREAM-ASN (nsample = 11,935 
participants; ngenetic variants = 7.8M); λgenomic inflation = 1.022. CREAM-EUR-ASN (nsample = 56,127 participants; ngenetic variants = 9.3M); 













Shown is the Manhattan plot depicting P values for association of the meta-analysis of CREAM-EUR&ASN and 23andMe 
(nsample=160,420 participants; ngenetic variants = 11M), highlighting new (P < 5 × 10−8 for the first time; green) and known (dark 




Supplementary Figure 6: Lambdas of all cohorts and fixed effects meta-analyses
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Supplementary Figure 7: LD-score regressions per ancestry of CREAM and 23andMe 
 
 
We used Popcorn57 to investigate ancestry-related differences in the genetic architecture of refractive 
error and myopia. Pairwise analyses were carried out using the GWAS summary statistics from the 
23andMe (n=104,292), CREAM-EUR (n=44,192) and CREAM-EAS (n=9,826) meta-analyses. Only 
SNPs with MAF ≥ 5% were included, resulting in a final set of 3,625,602 SNPs for analyses involving 








Supplementary Figure 8: Effects comparison SphE and AODM using different p-value thresholds  
 
Shown are the graphs for the comparison of the effects, SphE and AODM, using different p-value 
thresholds. These p-values are derived from the meta-analysis of stage 1 and 2, i.e. CREAM and 
23andMe. Red line = regression line; n = number of genetic variants tested at different P value thresholds 
(-log10p > 0.5 – -log10p >5); concordance =  concordance of correlation coefficient; slope = slope of 




Supplementary Figure 9: Top canonical pathways of Ingenuity Pathway Analysis  
A       B 








C      D 
 







The 197 of the 208 genes annotated to the top hits identified at Stage 3 were present in the IPA database 
and mapped to networks and pathways. The networks were identified by right-tailed Fisher’s exact tests. 
Genes within the network indicated in grey are genes associated with refractive error. A) Glutamate 
receptor signaling, P value = 1.56E-4; B) Factors Promoting Cardiogenesis in Vertebrates, P value = 
1.78E-4; C) CREB Signaling in Neurons; P value = 1.37E-3; D) Human Embryonic Stem Cell 
Pluripotency, P value = 1.83E-3  
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Supplementary Figure 10: Locus Zoom plots of RNA gene regions 
 
Regional plots of the RNA genes depicting the p-values derived from the meta-analysis of stage 3 (n=160,420), 
linkage disequilibrium and recombination ratio. Some of the RNA  genes were not depicted by the Locus Zoom 
software, in which case they were added as the red regions between the genes annotated by Locus Zoom; dist, 













Supplementary Figure 11: Locus Zoom plots of dopamine pathway regions  
 
Regional plots of the key genes in the dopamine pathway depicting the p-values derived from the meta-analysis of 
















Study Name Origin Study design n age (sd) % female mean SE
1958 British Birth Cohort United Kingdom population based study 1658 42.00 (0.00) 46.0 -0.96 (2.003)
ALIENOR France population based study 509 79.15 (4.06) 56.8 0.98 (1.97)
ALSPAC-Mothers United Kingdom population based study 1865 45.02 (4.53) 100.0 -0.76 (2.16)
ANZRAG Australia POAG cases 648 79.02 (12.08) 49.3 -0.21 (2.41)
AREDS United States population based study 1842 68.08 (4.71) 59.0 0.54 (2.16)
BATS Australia population based twin study 158 26.52 (2.41 56.3 -0.51 (1.15)
BMES Australia population based study 1896 67.09 (9.16) 57.3 0.62 (2.12)
Croatia-Korcula Croatia population based study 822 56.33 (13.34) 64.8 -0.15 (1.60)
Croatia-Split Croatia population based study 344 51.95 (13.02) 61.1 -1.27 (1.57)
Croatia-Vis Croatia population based study 527 56.29 (13.30) 60.0 -0.13 (1.74)
DCCT United States clinical trial 791 31.43 (4.13) 43.2 -1.47 (0.80)
EGCUT Estonia population based study 904 56.00 (17.00) 61.2 0.33 (3.36)
EPIC-Norfolk United Kingdom population based study 1084 68.81 (7.55) 56.3 0.34 (2.27)
ERF The Netherlands family based study 2610 48.72 (14.17) 55.0 0.13 (2.03)
FECD United States case-control  (controls only) 393 71.50 (9.18) 60.2 -0.14 (2.49)
FITSA Finland population based twin study 329 68.56 (3.35) 100.0 1.22 (1.71)
Framingham United States population based study 2729 55.60 (8.90) 42.5 0.03 (2.410)
Gutenberg Health Study 1 Germany population based study 2738 55.52 (10.81) 48.6 -0.38 (2.45)
Gutenberg Health Study 2 Germany population based study 1140 54.81 (10.81) 50.4 -0.41 (2.57)
KORA Germany population based study 2372 55.14 (11.79) 67.0 -0.25 (2.22)
OGP Talana Italy population based study 509 51.43 (19.51) 59.2 -0.10 (1.67)
ORCADES United Kingdom population based study 1165 55.83 (13.76) 61.0 0.09 (2.07)
Rotterdam Study I The Netherlands population based study 5787 68.84 (8.84) 59.4 0.83 (2.55)
Rotterdam Study II The Netherlands population based study 2038 64.24 (7.75) 54.4 0.49 (2.49)
Rotterdam Study III The Netherlands population based study 2950 56.91 (6.54) 55.9 -0.28 (2.60)
TEST Australia population based twin study 267 46.10 (12.25) 50.3 -0.54 (1.99)
Twins UK United Kingdom population based twin study 4342 53.83 (11.12) 92.2 -0.34 (2.72)
WESDR United States case-control from population based study 295 34.63 (8.05) 51.2 -1.53 (2.02)

















Study Name Origin Study design n age (sd) % female mean SE
Beijing Eye Study China population based study 590 62.13 (8.51) 66.1 -0.06 (1.87)
Nagahama Japan population based study 2730 51.29 (14.03) 66.6 -1.69 (2.78)
SCES Singapore (Chinese) population based study 1724 57.54 (8.99) 48.6 -0.77 (2.65)
SIMES Singapore (Malay) population based study 2275 58 (10.81) 50.9 -0.05 (1.86)
SINDI Singapore (Indian) population based twin study 2110 55.82 (8.82) 48.6 0.01 (2.14)
SP2-1M Singapore population based study 818 46.81 (10.16) 37.7 -1.81 (2.85)
SP2-610 Singapore population based study 871 48.54 (11.32) 80.4 -1.51 (3.00)
STARS PARENT Singapore population based study 817 38.61 (5.345) 49.0 -2.75 (2.85)
11935
Study Name Origin Study design n mean age of onset of myopia (sd) % female
23andMe_V2 United States population based study 12128 13.6 (5.8) 45.9




CREAM-EUR Study Name Phenotyping method Genotyping chip Pre-imputation QC metrics (exclusion criteria)
N  excluded individuals 
Post-QC Prephasing Imputation method GWAS software
1 1958 British Birth Cohort Autorefractor Nikon Retinomax 2 Illumina Human1M-Duo Beadchip
For MAF 0-0.05: SNP call rate of < 99%; for MAF >=0.05 SNP: call rate < 95%; p_HWE < 1x10-6; Sex 
disconcordance with reported, disconcordance with know controls/ repeats
0 ShapeIt IMPUTE2 SNPtest
2
ALIENOR Autorefractor Luneau SPEEDY K Illumina Human 610-Quad BeadChip
SNPs: MAF <= 0.01, p_HWE <= 1e-6, SNP Call rate <= 0.98.
Individuals: exclusion based on missingness + exclusion of duplicated/related individuals, individuals 
with discordance between clinical and genetic sex, or individuals with evidence of non-European 
20 SHAPEIT2 IMPUTE2 SNPtest
3 ALSPAC-Mothers Autorefractor Canon R50 Illumina 660W-Quad BeadChip MAF <0.01, p_HWE <1x10-7, SNP call rate <95% 8196 SHAPEIT2 Minimac mach2qtl
4 ANZRAG Refractive details were obtained from clinical notes Illumina Omni 1M/Illumina Omni Express
MAF <0.01, p_HWE <5x10-10, SNP call rate <97%, individual call rate<97%. Identity by descent was 
computed in PLINK based on autosomal markers, with one of each pair of individuals with relatedness 
of > 0.2 removed. Participants with PC1 or PC2 values > 6 standard deviations from the known northern 
European ancestry group were excluded. 24 IMPUTE2 IMPUTE2 SNPtest
5 AREDS Subjective Refraction Illumina HumanOmni2.5-4v1_H array
MAF <0.02, p_HWE <1x10-4, SNP call rate <98%,  individual call rate < 98%, used Illumina annotation to 
identify and flip all the SNPs where the TOP allele was not on the “+” strand 0 SHAPEIT2 IMPUTE2 Plink
7 BMES Autorefractor Zeiss Humphrey‐530 Illumina 670 Quad Custom Chip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 95% 227 MACH Minimac ProbABEL
6 BATS Autorefractor Zeiss Humphrey‐598 Illumina HumanHap 610-Quad array MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 0 MACH Minimac MERLIN
8 Croatia-Korcula Auto Ref/Keratometry NIDEK ARK30 Illumina 370CNV-Quad v1 BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 92 SHAPEIT2 IMPUTE2 ProbABEL
9 Croatia-Split Auto Ref/Keratometry NIDEK ARK30 Illumina 370CNV-Quad v3 BeadChip and OMNI MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 41 SHAPEIT2 IMPUTE2 ProbABEL
10 Croatia-Vis Auto Ref/Keratometry NIDEK ARK30 Illumina HumanHap300 v1.0 BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 65 SHAPEIT2 IMPUTE2 ProbABEL
11 DCCT Subjective Refraction Illumina Human-1M BeadChip Sample QC: gender mismatch with typed X-linked markers (n=3), call rate < 0.95 (n=0), genotype 
discrepancy with an earlier study (n=58), autosomal heterozygosity > 0.32 (n=0), cryptic relatedness 
(n=2), self-reported ethnicity other than white (n=50), outliers in PCA (n=24) 
113 SHAPEIT2 IMPUTE2 SNPtest
12 EGCUT Eye glass prescriptions Illumina Omni Express MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 0 IMPUTE2 IMPUTE2 SNPtest
13 EPIC-Norfolk Autorefractor Zeiss Humphrey‐500 Affymetrix GeneChip Human Mapping 500K Array Set
SNP QC: callrate (95% minimum, male-specific on Y), cluster pattern (using Affymetrix SNPolisher), 
plate effect on minor allele frequency, Hardy Weinberg p < 1e-8. Sample QC: CEL file not generated 
(raw image quality to poor to process), DishQC < 0.82 (poor fluorescence signal contrast), Step 1 call 
rate < 97% (calculated on a subset of SNPs, intended to ensure clustering uses only good quality data), 
Sample identity unclear (lab team flagged, or unexpected duplicate or non-duplicate), Sex 
discordance or other sex chromosome abnormality detected, Final sample callrate < 97%, 
Heterozygosity outlier (calculated separately for SNPs with minor allele frequency >1% and <1%), Rare 
allele count outlier (unusually high number of singleton, doubleton or tripleton counts), For 
duplicate/triplicate samples, only the sample with the highest call rate was kept, After this cleaning, 
there were no ethnic outliers to remove.
N/A SHAPEIT2 IMPUTE2 SNPtest
14 ERF Topcon RM-A2000 autorefractor Illumina 6K, 318K, 350K, 610K, Affymetrix 250K MAF <0.005, p_HWE < 1x10-8, SNP call rate < 98% 1048 MACH Minimac ProbABEL
15 FECD Subjective Refraction HumanOmni2.5-Quad BeadChip MAF < 0.02, p_HWE < 1x10-4 SNP call rate < 98%, individual call rate < 98%, > 1 Mendelian error 0 SHAPEIT2 IMPUTE2 Plink
16 FITSA TOPCON AT Illumina HumanCoreExome MAF < 0.01, p_HWE < 1x10-6, SNP call rate < 95% 4 SHAPEIT2 IMPUTE2 SNPtest
17 Framingham Subjective Refraction Affymetrix Mapping500K (Nsp & Sty) + 50K HumanHap 
supplement
Individual-level QC: Non-caucasian by history, individual missing genotypes > 0.10, mendelian 
inconsistencies > 0.1,; Marker-level QC: MAF < 0.01, SNP call rate < 97%, p_HWE in unrelateds < 10e-05;  
Note: Baseline QC was carried out on all genotyped Framingham Study Participants (N=9,270) in order 
maximize the accuracy of marker-level and family-level statistics. 
N/A SHAPEIT2 IMPUTE2 MixABEL
18 Gutenberg Health Study 1
Zeiss Humphrey® Automated Refractor/Keratometer 
(HARK) 599™ Affymetrix Genome-Wide Human SNP Array 6.0 MAF ≤0.01, p_HWE≤0.0001, SNP call rate ≤ 98% N/A IMPUTE2 IMPUTE2 SNPtest
19 Gutenberg Health Study 2
Zeiss Humphrey® Automated Refractor/Keratometer 
(HARK) 599™ Affymetrix Genome-Wide Human SNP Array 6.0 MAF ≤0.01, p_HWE≤0.0001, SNP call rate ≤ 98% N/A IMPUTE2 IMPUTE2 SNPtest
20 KORA Nikon Retinomax and Eye glass prescriptions Illumina Omni 2.5/Illumina Omni Express MAF < 0.01, p_HWE < 1x10-6, SNP call rate < 98% N/A SHAPEIT2 IMPUTE2 SNPtest
21 OGP Talana Autorefractor Topcon RK-8100 Affymetrix GeneChip Human Mapping 500K MAF <0.05, p_HWE < 1x10-4, SNP call rate < 95% 0 SHAPEIT2 IMPUTE2 ProbABEL
22 ORCADES KOWA Illumina HumanHap 300v2, 370CNV-Quad and OMNI MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 98 SHAPEIT2 IMPUTE2 ProbABEL
23 Rotterdam Study I Topcon RM-A2000 autorefractor
Illumina HumanHap 550-Duo v3 BeadChip, Illumina 
HumanHap 610-Quad BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 504 MACH Minimac ProbABEL
24 Rotterdam Study II Topcon RM-A2000 autorefractor Illumina HumanHap 550-Duo v3 BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 119 MACH Minimac ProbABEL
25 Rotterdam Study III Topcon RM-A2000 autorefractor Illumina HumanHap 610-Quad BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 98 MACH Minimac ProbABEL
26 TEST Autorefractor Zeiss Humphrey‐598 Illumina HumanHap 610-Quad BeadChip MAF <0.01, p_HWE < 1x10-6, SNP call rate < 98% 0 MACH Minimac MERLIN
27 Twins UK ARM-10 Autorefractor (Takagi Ltd) Illumina 610K, Illumina 317K For MAF 0-0.05: SNP call rate of < 99%; for MAF >=0.05 SNP: call rate < 95%; p_HWE < 1x10-6; 
Heterozygosity within 3SD (individuals); Sex disconcordance with reported, disconcordance with know 
IMPUTE2 SNPtest
28 WESDR Subjective Refraction Illumina Omni1-Quad BeadChip Sample QC: gender mismatch with typed X-linked markers (n=9), cryptic relatedness (n=24), 
autosomal heterozygosity > 0.3 (n=5), call rate < 0.95 (n=29), self-reported ethnicity other than white 
(n=3), outliers in MDS analysis (n=4); SNP QC: duplicate SNPs, high missing rate [maf>=0.05 & 
MISS>0.05, 0.05>MAF>=0.01 & MISS>0.01, MAF<0.01 & MISS>0], p_HWE<1E-9
58 SHAPEIT2 IMPUTE2 SNPtest
29 YFS NIDEK AR-310AR autorefractor Illumina 670K Custom Array MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95% 963 SHAPEIT1 IMPUTE2 SNPtest
CREAM-ASN Study Name phenotyping method GWAS chip QC parameters genotypes
N  excluded individuals 
Post-QC Prephasing Imputation method GWAS software
1 Beijing Eye Study Canon RK-5 Auto Ref-Keratometer Illumina Human 610 Quad Beadchip MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%, Samples with cryptic relatedness, population structure ascertainment and excessive heterogeneity156 MACH Minimac SNPtest
2 Nagahama Nidek-ARK530A Illumina HumanHap 610-Quad BeadChip, Illumina Human 
Omni2.5-8 BeadChip, Illumina Human Omni2.5-Quad 
BeadChip, Illumina Human Omni2.5S-8 BeadChip, Illumina 
Infinium Exome-24 v1.0 BeadChip MAF<0.01, p_HWE<1x10-7, SNP call rate<90%, individual call rate<90% 0
SHAPEIT2 Minimac Plink
3 SCES Canon RK-5 Auto Ref-Keratometer Illumina Human 610 Quad Beadchip
MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%, Samples with cryptic relatedness, 
population structure ascertainment and excessive heterogeneity 63 MACH Minimac SNPtest
4 SIMES Canon RK-5 Auto Ref-Keratometer Illumina Human 610 Quad Beadchip MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95% 530 MACH Minimac SNPtest
5 SINDI Canon RK-5 Auto Ref-Keratometer Illumina Human 610 Quad Beadchip
MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%,Samples with cryptic relatedness, 
population structure ascertainment and excessive heterogeneity 415 MACH Minimac SNPtest
6 SP2-1M Canon RK-5 Auto Ref-Keratometer Illumina Human1M-Duo v3 BeadChip
MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%,Samples with cryptic relatedness, 
population structure ascertainment and excessive heterogeneity 63 MACH Minimac SNPtest
7 SP2-610 Canon RK-5 Auto Ref-Keratometer Illumina Human 610 Quad Beadchip
MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%,Samples with cryptic relatedness, 
population structure ascertainment and excessive heterogeneity 321 MACH Minimac SNPtest
8 STARS Canon RK-F1 Autorefractor, Welch Allyn retinoscopy Illumina Human 610 Quad Beadchip
MAF <0.01, p_HWE < 1x10-6, Sample and SNP call rate < 95%, samples with >1% SNPs showing 
Mendelian error,Samples with cryptic relatedness, population structure ascertainment and excessive 26 MACH Minimac SNPtest
23andMe Study Name phenotyping method GWAS chip QC parameters genotypes
N  excluded individuals 
Post-QC Prephasing Imputation method GWAS software
1 23andMe_V2 Questionaire Illumina!HumanHap550+ BeadChip MAF < 0.001,  individuals who have <97% European ancestry,  p_HWE < 1x10-20, SNP call rate < 95%, or 
with large allele frequency discrepancies compared to the 1000 Genomes reference data
N/A Beagle Minimac Cox proportional hazards model using 
R and custom GWAS software
2 23andMe_V3 Questionaire OmniExpress+ BeadChip MAF < 0.001,  individuals who have <97% European ancestry,  p_HWE < 1x10-20, SNP call rate < 95%, or 
with large allele frequency discrepancies compared to the 1000 Genomes reference data
N/A Beagle Minimac Cox proportional hazards model using 
R and custom GWAS software





Supplementary Table 5: Index SNPs HapMap II from CREAM and 23andMe 




CREAM P value Locus Name 23andMe 23andMe HR (CI) 23andMe P 
value
A1 Freq1 Zscore P-value Direction HetISq HetChi HetDf HetPval N
1 rs1652333 1 207470460 G/A CD55 -0.1116533 0.0160072 3.05434E-12 - - - G 0.6769 -7.242 4.42E-13 ++ 81.7 5.457 1 0.01949 160136
rs1656404 233379941 A/G PRSS56 -0.1528567 0.0235048 7.86186E-11 - - - A 0.1733 -11.253 2.25E-29 -- 75 3.999 1 0.04554 156056
rs1550094 233385396 A/G - - - - PRSS56 1.087 (1.067 - 1.107) 5.8E-18 A 0.7005 12.738 3.64E-37 ++ 88.9 8.996 1 0.002705 159422
3 rs17400325 2 178565913 T/C - - - - PDE11A 1.144 (1.099 - 1.190) 8.7E-11 T 0.9513 7.994 1.30E-15 ++ 92.1 12.616 1 0.0003824 150322
4 rs17412774 2 146773948 A/C - - - - PABPCP2 0.933 (0.917 - 0.950) 1.5E-14 A 0.5506 -8.568 1.05E-17 -- 88.9 9.033 1 0.002652 159506
5 rs17428076 2 172851936 C/G - - - - DLX1 0.935 (0.916 - 0.955) 1.4E-10 C 0.768 -8.183 2.77E-16 -- 88.8 8.899 1 0.002854 160151
6 rs1881492 2 233406998 T/G CHRNG -0.139 0.021 5.15E-11 - - - T 0.2008 -10.252 1.16E-24 -- 0 0.338 1 0.5611 159506
7 rs13091182 3 141133960 G/A - - - - ZBTB38 0.940 (0.923 - 0.958) 3.6E-11 G 0.3352 -8.001 1.23E-15 -- 83.8 6.166 1 0.01303 153193
8 rs14165 3 53847408 A/G CACNA1D 0.096 0.017 2.14E-08 - - - A 0.3014 6.25 4.10E-10 ++ 0 0.061 1 0.8045 149655
9 rs5022942 4 81959966 G/A - - - - BMP3 1.076 (1.054 - 1.098) 4.2E-12 G 0.2416 9.258 2.08E-20 ++ 89.8 9.848 1 0.0017 160150
10 rs9307551 4 80530671 A/C LOC100506035 -0.099 0.017 1.09E-08 - - - A 0.2452 -7.972 1.56E-15 -- 0 0.237 1 0.6265 160149
rs12205363 129834629 C/T LAMA2 0.235 0.033 1.79E-12 - - - C 0.9317 15.975 1.91E-57 ++ 96.6 29.438 1 5.78E-08 150327
rs12193446 129820038 A/G - - - - LAMA2 0.788 (0.763 - 0.813) 6.8E-53 A 0.9063 -19.431 4.21E-84 -- 98.4 60.996 1 5.72E-15 150269
A/C KCNQ5 -0.112 0.019 4.18E-09 - - -
A/C - - - - KCNQ5 0.909 (0.893 - 0.926) 2.7E-25
rs7837791 60179086 T/G TOX 0.106 0.015 3.99E-12 - - T 0.4816 11.59 4.64E-31 ++ 53 2.127 1 0.1447 160152
chr8:60178580 60178580 C/G - - - - TOX/CA8 0.914 (0.897 - 0.931) 4E-22 C 0.6415 -13.137 2.03E-39 -- 87 7.678 1 0.00559 160128
14 rs4237036 8 61701057 C/T CHD7 0.089 0.016 1.82E-08 - - - C 0.6669 5.205 1.94E-07 ++ 0 0.984 1 0.3212 160148
rs7829127 A/C ZMAT4 -0.116 0.018 3.69E-10 - -
rs7829127 A/G - - - - SFRP1 0.901 (0.880 - 0.923) 1.8E-18
rs11145465 71766593 A/C TJP2 -0.124 0.021 7.26E-09 - - - A 0.2122 -9.546 1.35E-21 -- 46.3 1.863 1 0.1722 153174
rs11145746 71834380 G/A - - - - TJP2 1.087 (1.063 - 1.112) 5.2E-13 G 0.2056 9.098 9.22E-20 ++ 68 3.127 1 0.07698 153113
17 rs7042950 9 77149837 G/A RORB -0.0964935 0.0175941 4.14842E-08 - - G 0.7323 -6.797 1.07E-11 -- 0 0.012 1 0.9122 160153
18 rs10882165 10 94924324 T/A CYP26A1 -0.107 0.016 1.03E-11 - - - T 0.5869 -6.155 7.49E-10 -- 69.1 3.237 1 0.07198 155329
19 rs6480859 10 79081948 C/T - - - - KCNMA1 1.058 (1.039 - 1.077) 7.3E-10 C 0.363 8.202 2.36E-16 ++ 79 4.765 1 0.02904 160148
20 rs7084402 10 60265404 G/A BICC1 -0.108 0.015 2.06E-13 - - - G 0.5277 -8.828 1.07E-18 -- 0 0.428 1 0.5129 160020
21 rs745480 10 85986554 C/G - - - - RGR 1.063 (1.044 - 1.081) 8E-12 C 0.5109 8.314 9.26E-17 ++ 67.3 3.055 1 0.0805 159504
22 rs11601239 11 105556598 C/G GRIA4 -0.0949272 0.0163137 5.92475E-09 - - - C 0.485 -6.824 8.84E-12 -- 0 0.008 1 0.9281 160118
23 rs1381566 11 40149607 T/G - - - - LRRC4C 1.149 (1.122 - 1.176) 2.3E-30 T 0.81 13.593 4.43E-42 ++ 97.6 40.832 1 1.66E-10 157519
24 rs2155413 11 84634790 C/A - - - - DLG2 1.061 (1.043 - 1.080) 1.7E-11 C 0.4823 7.755 8.85E-15 ++ 92.4 13.078 1 0.0002987 159504
25 rs12229663 12 71249996 G/A PTPRR 0.099 0.017 5.47E-09 - - - G 0.7527 7.362 1.81E-13 ++ 0 0.221 1 0.6386 160133
C/G RDH5 0.119 0.017 4.44E-12 - - -
C/G - - - - RDH5 0.890 (0.870 - 0.911) 1.3E-23
27 rs2184971 13 100818092 G/A PCCA 0.085 0.015 2.11E-08 - - - G 0.5441 5.232 1.68E-07 ++ 0 0.51 1 0.4751 160146
28 rs4291789 13 100672921 C/G - - - - ZIC2 1.069 (1.046 - 1.092) 2.10E-08 C 0.6723 7.899 2.80E-15 ++ 86 7.146 1 0.007514 159988
29 chr14:54413001 14 54413001 G/C - - - - BMP4 0.946 (0.929 - 0.963) 1.1E-09 G 0.4657 -7.118 1.09E-12 -- 73.6 3.784 1 0.05174 160104
30 rs1254319 14 60903757 A/G SIX6 -0.088 0.015 1.00E-08 - - - A 0.3322 -5.602 2.12E-08 -- 76.3 4.226 1 0.03981 160153
rs4778879 79372875 G/A RASGRF1 -0.102 0.015 4.25E-11 - - - G 0.5823 -9.898 4.24E-23 -- 0 0.684 1 0.4081 160068
rs28412916 79378167 A/C - - - - RASGRF1 1.067 (1.048 - 1.086) 8.2E-13 A 0.5874 9.944 2.68E-23 ++ 0 0.161 1 0.6886 160152
T/A GJD2 0.1582561 0.019821 1.44329E-15 - - -
T/A - - - - GOLGA8B/GJD2 1.089 (1.070 - 1.108) 6.9E-22
7459683 G/C A2BP1 0.118 0.019 5.64E-10 - - -
7459683 G/C - - - - RBFOX1 1.102 (1.082 - 1.122) 4.1E-26
34 rs17183295 17 31078272 T/C MYO1D -0.131 0.02 9.66E-11 - - - T 0.1901 -8.177 2.91E-16 -- 0 0.41 1 0.522 152597
T/A SHISA6 0.101 0.015 7.29E-11 - - -
T/A - - - - SHISA6 1.074 (1.055 - 1.093) 5.2E-15
36 rs4793501 17 68718734 C/T KCNJ2 0.08040793 0.0144771 2.78971E-08 - - - C 0.5748 7.212 5.53E-13 ++ 0 0.288 1 0.5917 160150






1000G meta-analysis results of CREAM and 23andMe topSNPs  from HapMapII 
for Refractive Error and Age of Diagnosis Myopia
96.3 26.829 1 2.22E-07 160122
0.0002774 160132
11407259
G 0.3535 13.693 1.13E-42
92.4
0.001132 160091A 0.5905 -14.555 5.43E-48 -- 90.6 10.598 1
A 0.7917 -10.911 1.02E-27 --
24.566 1 7.18E-07 157544T 0.2115 13.766 4.06E-43 ++ 95.9






15 T 0.4748 17.075 2.28E-65
T 0.4146 9.46E-2911.125


























Supplementary Table 6. LD score regression analysis and heritability explained by common SNPs 
 
Sample Ref. panel1 N2 GC
LD score regression3 
Intercept (se) h2 (se) p 
CREAM-
EUR 
EUR 44.192 1.165 1.023 (0.008) 0.214 (0.015) 2.4 x 10e-49 
23andMe EUR 104.292 1.108 0.892 (0.009) 0.172 (0.009) 1.6 x 10e-81 
CREAM-
EAS 
EAS 9.826 1.017 1.001 (0.006) 0.053 (0.040) 0.190 
 
1Reference panel used to calculate LD scores. 
2The maximum sample size; not all markers were genotyped in all samples and therefore this number 
will vary from marker to marker. 
3LD score regression intercept and heritability estimate (p-value relates to a test of the null hypothesis 
of h2=0; intercepts above 1 give evidence of inflated association statistics due to residual population 





Supplementary Table 7: Exonic protein-altering variants 
 
Marker name Gene name P-value meta-
analysis Stage 3  
chr:pos Mutation Amino 
acid 
change 
rs5442 GNB3 5.48E-15 12:6954864 missense Gly > Ser 
rs807037 KAZALD1 4.59E-08 10:102824349 missense Gly > Ala 
rs1550094 PRSS56 3.64E-37 2:233385396 missense Ala > Thr 
rs1064583 COL10A1 6.90E-11 6:116446576 missense  Met > Thr 
rs6420484 TSPAN10 2.80E-09 17:79612397 missense Tyr > Cys 
rs2303635 AMOTL2 1.14E-09 3:134086356 missense Ala > Pro 
rs35337422 RD3L 2.19E-10 14:104407243 missense Ile > Arg 
rs17400325 PDE11A 1.30E-15 2:178565913   missense Tyr > Cys 
 
P values derived from stage 3 meta-analysis (n=160,420) 






Supplementary Table 8: Post-GWAS analyses additional genes 
     
 
P values derived from stage 3 meta-analysis (n=160,420)  
Gene Chr Start End N SNPs per 
region tested
P value stage 3 
meta-analysis
Analysis Remarks Novel 
gene #
MIR6512 2 178178533 178178610 72 4.52E-07 fastBAT 1
RPP14 3 57062260 58625174 5003 4.46E-07 fgwas 2
IL4 5 132009678 132018368 1 1.70E-06 Eugene 3
HMGN4 6 26538633 26546482 7 1.00E-07 Eugene, fgwas 4
HIST1H2AG 6 27100816 27101314 58 1.38E-06 fastBAT 5
CDKAL1 6 19752146 21152237 5010 6.97E-08 fgwas Genome wide significant in 
Discovery stage 
POU6F2 7 39017608 39504390 526 5.33E-07 fastBAT 6
CHD7 8 61591323 61780586 248 5.36E-07 fastBAT Significant in Discovery 
stage after Bonferroni's 
correction and established 
in HapMap II analysis in 2013
7
C8orf84 8 73887862 75301149 5019 2.87E-07 fgwas same locus 1 8
BC127738 8 73887862 75301149 5019 2.87E-07 fgwas same locus 1 9
TRAF1 9 123664671 123691451 3 1.20E-06 Eugene 10
C5 9 123714613 123812554 109 1.10E-06 fastBAT 11
C10orf11 10 77542518 78317126 670 1.14E-06 fastBAT Genome wide significant in 
Discovery stage 
TLX1 10 102891060 102897546 132 5.88E-07 fastBAT, fgwas 12
ACP2 11 47260853 47270457 4 1.10E-06 Eugene 13
SYTL2 11 85405267 85522184 4 1.60E-06 Eugene 14
CCDC89 11 85394892 85397320 74 5.50E-07 fastBAT 15
HNRNPKP3 11 43283053 43290919 115 4.72E-07 fastBAT Genome wide significant in 
Discovery stage 
TP53AIP1 11 128804626 128813294 174 1.73E-07 fastBAT 16
ANKRD9 14 102973179 102976136 6 4.00E-07 Eugene 17
CRHR1-IT1 17 4369769 43725582 3 1.00E-07 Eugene 18
LOC101927557 17 55599608 55600958 190 1.12E-06 fastBAT 19
TNFSF12 17 7452374 7461207 117 1.82E-06 fastBAT Genome wide significant in 
Discovery stage 
FAM83C 20 33873533 33880225 71 1.67E-06 fastBAT 20
TMEM184B 22 38615297 38669040 164 1.72E-06 fastBAT 21
LARGE 22 32001050 33156201 5019 4.13E-07 fgwas same locus 2 22
ISX 22 32001050 33156201 5019 4.13E-07 fgwas same locus 2 23
LOC388906 22 39756985 41941243 5019 2.00E-07 fgwas same locus 3 24
BC038245 22 39756985 41941243 5019 2.00E-07 fgwas same locus 3 25
61 
 
Supplementary Table 9: Predictive power of the polygenic score in Rotterdam Studies (I, II, III) 






R2 P-value % variance 
explained† 
Reference**     0.052 NA 5.2 
S1 5.00E-08 152 0.099 5.35E-122 4.7 
S2 5.00E-07 214 0.101 1.17E-127 4.9 
S3 5.00E-06 334 0.106 2.24E-139 5.4 
S4 5.00E-05 661 0.112 2.33E-155 6.0 
S5 5.00E-04 1815 0.122 1.91E-181 7.0 
S6 0.005 7303 0.130 1.19E-203 7.8 
S7 0.01 11763 0.129 2.20E-201 7.7 
S8 0.05 37999 0.124 2.91E-188 7.2 
S9 0.1 63106 0.119 8.93E-176 6.8 
S10 0.5 183871 0.113 1.32E-159 6.2 
S11 0.8 228198 0.113 3.25E-158 6.1 
S12 1 243938 0.113 5.53E-158 6.1 
* Meta-analysis results stage 3 (CREAM and 23andME) excluding RS-I-II-III (n=148,645)         
**Reference model, mean Spherical Equivalent ~ age + sex + first 5PCs + cohort 
† Variance explained by each score (S1-S12) was calculated by substraction of a full model 
(reference + score) from a reduced model (reference only) 
Estimating the incremental R2 from including the polygenic score (S1-S12) in a regression of 














Supplementary Table 12: RNA genes – region look-ups 
 




5S_rRNA 5S ribosomal RNA Ribosomal RNA 1:163479274-
163479385
rs1556867












rs12998513 LOC102723927 also in region










BC030753/NFIA-AS2 cDNA clone - transcript of NFIA-











rs12193446 Overlap with LAMA2 region
BC039327/CASC17 cDNA clone - transcript of 




17:69093915-69198318 rs4793501 Diseases associated with CASC17 include Prostate 
Cancer Susceptibility (genecards).









8:74153659-74171737 Gene based 
(rs16938625 closest 
GWS tophit)
CRHR1-IT1 Long Intergenic Non-Protein 
Coding RNA 2210; C17orf69
Long intergenic non-
protein coding RNA
17:43716341-43723595 Gene based 
(rs117118311 
closest GWS tophit)
D43770/LINC01152 RNA of LINC01152 Long intergenic non-
protein coding RNA
17:70026957-70035822 rs7207217 This RNA may play a significant role in differentiation 
or sex determination (NCBI)









rs1237670 Overlap with LINC01356 region





LINC00340/CASC15 CASC15, Cancer Susceptibility 
15 (Non-Protein Coding); Lnc-
SOX4-1; Long intergenic non-









LINC00461 long intergenic non-protein 
coding RNA 461; EyeLinc1; 




5:87836597-87980620 rs7737179 Highly conserved and expressed in the human 
macula (PMID: 23562822). ECONEXIN was the most 
highly conserved intergenic lncRNA containing 
83.0% homology with the mouse ortholog 
(C130071C03Rik) for a region over 2500 bp in 
length within its exon 3. Expressions of ECONEXIN 
and C130071C03Rik were significantly upregulated 
in both human and mouse glioma tissues. PMID: 
28368417
LINC00862 C1orf98; SMIM16;Small 
Integral Membrane Protein 16; 

















LOC100508120/GMDS-AS1 GMDS antisense RNA 1 Uncharacterized non-
protein coding RNA
6:2245987-2413825 rs10458138




17:55599609-55600958 Gene based 
(rs28488643 closest 
GWS tophit)





SNORA40 Small nucleolar RNA 40, H/ACA 
box 40 
Small nucleolar RNA 2:16380471-16380563 rs28658452
SNORA51 Small nucleolar RNA 51, H/ACA 
Box 51; ACA51 SnoRNA; ACA51 
Small nucleolar RNA 8:60049931-60050061 rs72621438





TRNA_Ala Alanine tRNA transfer RNA 14:89445442-89445514 rs17125093
TRNA_Gln Glutamine tRNA transfer RNA 17:47269890-47269961 rs11654644
TRNA_Ser Serine tRNA transfer RNA 6:28180815-28180896 rs1150687
U6 RNA, U6 Small Nuclear Small nucleolar RNA 4:83095700-83095806 rs2166181 Diseases associated with RNU6-1 
include Poikiloderma With Neutropenia. Among its 
related pathways are mRNA Splicing - Major 
Pathway and RNA transport. (genecards)
** These loci were not included in the UKEV replication analysis
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Supplementary Table 17: Genes in Dopamine pathway – region look-ups 
Gene Chromosome Start End 
NCBI Reference 
Sequence 
DRD1 5 174867675 174871163 NC_000005.9  
DRD2 11 113280317 113346413 NC_000011.9 
DRD3 3 113847499 113918254 NC_000003.11  
DRD4 11 637305 640706 NC_000011.9  
DRD5 4 9783258 9785633 NC_000004.11  
COMT 22 19929263 19957498 NC_000022.10 
DBH 9 136501485 136524466 NC_000009.11 
DDC 7 50526134 50633154 NC_000007.13 
MAOA X 43514155 43606071 NC_000023.10 
TH 11 2185159 2193107 NC_000011.9 
SLC6A3/DAT 5 1392905 1445543 NC_000005.9 
SLC6A4/SERT 17 28521337 28562986 NC_000017.10 
 
 
     
 
  
Gene Chr Start End N_SNPs tested Lowest P-value 
Stage 3 meta-
analysis
TopVariant Position Top 
Variant
COMT 22 19929263 19957498 3971 2.00E-04 rs4819854 19854659
DBH 9 136501485 136524466 5519 2.78E-04 rs191849948   136719162
DDC 7 50526134 50633154 4230 2.38E-04 rs2189432 51100959
DRD1 5 174867675 174871163 3733 3.58E-08 rs7449443 174720893
DRD2 11 113280317 113346413 3988 1.07E-04 rs188263557 113108780
DRD3 3 113847499 113918254 2915 9.41E-04 rs189807093  114022413
DRD4 11 637305 640706 4760 1.01E-04 rs80190876 680614
DRD5 4 9783258 9785633 5705 1.03E-04 rs57553236 9688140
MAOA X 43514155 43606071 1591 5.76E-03 rs73196113 43972237
SLC6A3/DAT 5 1392905 1445543 5846 2.35E-04 rs147426622 1652855
SLC6A4/SERT 17 28521337 28562986 2426 4.77E-04 rs113822901 28994581
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